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Abstract 
Cancer has been, and still remains, one of the most complicated diseases to treat. As a result of 
the side effects experienced from current cancer treatment methods, there has been a growing 
interest in the development of targeted drug delivery systems that can destroy cancer cells, but 
render healthy tissue unharmed. To address this challenge, magnetite nanoaggregates were 
synthesized through the precipitation of iron oxide in the presence of polymers, conjugated with 
folic acid for folate targeting, and loaded with curcumin for cancer treatment. The resulting 
magnetite nanoparticles were 10 – 20 nm in size and the aggregates formed varied in size 
depending on the ratio of polymers present. Furthermore, the ratio of polymers on the particle 
surfaces, in addition to the presence of folic acid, played a major role in sustaining curcumin 
release. In vitro studies with MDA-MB-231 and MDA-MB-468 cells revealed that the particles 
without curcumin exhibited low cytotoxicity up to 2 mg/mL in both cells lines. However, in the 
presence of curcumin, toxicity to MDA-MB-468 cells was observed. In addition, folic acid 
functionalized particles showed enhanced uptake in MDA-MB-468 cells, which express elevated 
levels of the folic acid receptor, in comparison to non-targeted particles, suggesting the 
possibility of selective delivery towards cancer cells.  
 
 
Keywords 
targeted cancer treatment, drug delivery, curcumin, folate receptor, magnetic nanoparticles, 
controlled drug release  
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Chapter 1  
1 Introduction 
1.1 Motivation and Cancer Treatment Overview 
For years researchers have been seeking a means of solving one of the toughest puzzles in the 
world; cancer. In 2013, there were approximately 1.6 million cases of cancer with 580,350 
deaths occurring in the United States,1 and 187,600 cases of cancers in Canada, of which 75,500 
cases resulted in death.2 Traditional treatment methods including one of, or a combination of, 
surgery, radiation therapy, and chemotherapy have been enhanced overtime which is evident by 
the high incidences of cured individuals. However, these treatment methods are still not flawless. 
Surgery is invasive, bearing many risks to the patient before and after the procedure. Radiation 
therapy involves both early side effects such as skin erythema, nausea, dryness, and itchiness, 
and late effects which include long term conditions such as vascular or neural damage, atrophy, 
and radiation-induced fibrosis.3 Both early and late side effects associated with radiation therapy 
are local, being manifested in the tissue that was irradiated. This outlines the main difference 
between radiation therapy and chemotherapy, as the latter causes systemic side effects 
(throughout the entire human body). The anti-cancer agents used in chemotherapy destroy 
rapidly dividing cells, whether cancerous or healthy. Therefore, there is a strong need for a 
technology that can direct chemotherapeutic agents to the tumour site once administered, thereby 
rendering healthy tissue unharmed.  
1.2 Drug Delivery Systems (DDS) for Cancer Treatment 
Today, many cancer awareness societies quote targeted therapy as one of the options of cancer 
treatment. Indeed, there has been a plethora of research aimed at the development of drug 
delivery systems (DDS) that can transport chemotherapeutics to the site of interest, thereby 
localizing the drug and decreasing or potentially eliminating side effects. Common drug delivery 
systems include liposomes, exosomes, micelles, dendrimers or different polymeric networks, and 
nanoparticles, which encompass a wide variety of different systems.4 
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1.2.1 Liposomes, Micelles, and Exosomes 
Lipid-based systems such as liposomes and micelles have been used for drug delivery and cell 
targeting due to their biocompatibility and ability to increase the bioavailability of many drugs.5 
Sardan et al. synthesized peptide amphiphile (PA)-incorporating liposomes for cell targeting.6 
Liposomes containing PA were made using a 7:8:1 ratio of 1, 2-dioleoyl-sn-glycero-3-
[phosphor-rac-(1-glycerol)] (DOPG), cholesterol (CHOL), and PA respectively using a 
curvature tuned preparation method. The amphiphilic nature of the system allowed for the 
incorporation of Rhodamine B and nile red as model hydrophilic and hydrophobic drugs, 
respectively. 
In other work, reduction-sensitive, shell-sheddable micelles synthesized using poly(ethylene 
glycol)-poly(ε-caprolactone) (PEG-PCL) copolymers were used to encapsulate doxorubicin for 
targeting of tumour cell nuclei.7  The authors reported more efficient release of doxorubicin 
when using reduction-sensitive versus non-reduction-sensitive micelles. Exosomes—endocytotic 
membrane vesicles excreted by many cells—are also used for drug encapsulation. Tian et al. 
focused on the delivery of doxorubicin, but using exosomes as delivery vehicles.8 Exosomes 
were obtained from immature dendritic cells (imDCs) of mice in order to reduce immunogenicity 
and toxicity, and then functionalized to express a common exosomal membrane protein 
(Lamp2b) conjugated to αv integrin iRGD peptide for tumour targeting.  
1.2.2 Hydrogels 
There has been extensive research involving hydrogels—materials composed of polymer chain 
networks—for targeted cancer treatment and other biomedical applications,9-11 with recent 
emphasis on “smart” hydrogels which are capable of changing their properties in response to 
certain stimuli such as temperature and pH.12 Thermoresponsive poloxamer hydrogels 
conjugated with linoleic acid-coupled Pluronic-F127 (Plu-CLA) were synthesized and loaded 
with docetaxel for the treatment of metastatic gastric cancer.13 The hydrogels remained in 
solution at room temperature for intraperitoneal injection, upon which gelation occurred at body 
temperature. The gelation along with the coupled Plu-CLA was noted to achieve more sustained 
release of docetaxel, with higher cancer cell destruction was reported for hydrogel-loaded 
docetaxel than docetaxel alone.  
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1.2.3 Dendrimers 
Dendrimers may be one of the oldest known drug delivery systems, dating back to the late 
1970’s, although their application as drug delivery vehicles or “host-guest” systems was not 
described at the time.14 However, for the past decade there has been a strong focus on the use of 
dendrimers as drug delivery systems for cancer treatment.15 Because dendrimers can be 
synthesized to incorporate a wide variety of anti-cancer agents, and functionalized to include 
various ligands capable of targeting cancer cell surface receptors, they make promising drug 
delivery vehicles. Modi et al. synthesized fluorescein-labeled generation 5 (G5) PAMAM 
dendrimers conjugated with FSH33 which is the binding domain of follicle stimulating hormone 
(FSH).16 Due to the high affinity of FSH33 to the FSH receptor (FSHR) present on the surface of 
ovarian cancer cells, the functionalized dendrimers showed significant uptake by ovarian cancer 
cells resulting in the down-regulation of survivin (an anti-apoptotic protein) meanwhile 
rendering normal non-FSHR expressing ovarian cells unharmed. 
1.2.4 Nanoparticles 
Several types of nanoparticles have been developed using a wide variety of different materials 
for the delivery of therapeutic agents. By definition, nanomaterials are materials or aggregates of 
materials in the size range of 1 – 100 nm.17 Li et al. proposed fluorescent theranostic silica 
nanoprobes for cancer cell imaging and growth inhibition.18 The nanoprobes were synthesized 
using a reverse emulsion method and functionalized to incorporate a cell targeting moiety 
(AS1411 aptamer) and 2'-O-methyl-modified miRNA-21 molecular beacon (miR-21-MB) to 
particularly recognize miRNA-21 present in breast cancer cells.  The authors reported 
monodisperse nanoprobes with an approximate size of 50 nm which demonstrated the ability to 
specifically target cancer cells and inhibit cell growth while simultaneously allowing for cancer 
cell and intracellular miRNA-21 imaging.   
In other work, Deng et al. co-encapsulated MiR-34a—an endogenous tumour suppressor 
molecule present in breast cancer cells –and doxorubicin into hyraluronic acid-chitosan 
nanoparticles, synthesized using an ionotropic gelation method in water, for breast cancer 
therapy.19 The size of nanoparticles containing both MiR-34a and doxorubicin increased as the 
amount of hyraluronic acid used in the formulation was increased, and the authors reported 
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sustained release of both components in the delivery system for up to 10 days. Furthermore, the 
study revealed that the co-delivery of MiR-34a and doxorubicin resulted in the enhancement of 
doxorubicin anti-tumour activity, in addition to suppression of cancer cell migration by targeting 
the Notch-1 signaling pathway.   
Rouhani et al. considered cancer treatment through oxidation therapy—the use of reactive 
oxygen species (ROS) as oxidant or anti-oxidant inhibitors to cause apoptosis or necrosis.20 The 
authors investigated poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with zinc 
protoporphyrin (ZnPP) as a heme oxygenase (HO)—an anti-oxidant enzyme known to play a 
role in cell growth and proliferation—inhibitor. The average size of the synthesized 
nanoparticles was precisely reported to be 100.12±5.345 nm with a smooth, spherical 
morphology, and showed potent cytotoxic effects as well as high cellular uptake in PC3 human 
prostate cancer cells. 
1.3 History of Metallic Compounds for Medical Treatments 
Among the various nanoparticles that have been investigated for therapeutic purposes are 
magnetic nanoparticles. Although there has been intensive research involving their use for 
diagnostic and therapeutic purposes in the last decade, the use of nanoparticles dates hundreds of 
years back. Daniel and Astruc described a detailed history of nanoparticles, specifically gold 
nanoparticles, as this was one of few metals present in ancient times.21 The authors make 
reference to a book written by Francisci Antonii in 1618 on colloidal gold, which is considered 
the first book on colloidal gold. The book gives detailed information regarding colloidal gold 
sols and their medical uses. He also went further to describe the appearance of a “soluble gold” 
in ancient Egypt and China, stating that the “curable powers” of this gold were appreciated until 
the Middle Ages. Also, it is noted that in 1676 a book published by Johann Kunckels mentions a 
drinkable light pink solution that contains metallic gold capable of curing several diseases.     
Although there was little evidence in past civilizations that these metallic compounds in fact 
cured diseases, today there is extensive research on the use of nanoparticles for the use in 
biomedical applications. For medical applications, a balance between biocompatibility and large 
magnetic moments must be achieved, which is why iron-based nanoparticles (such as iron 
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oxides) are ideal candidates for medical applications compared to others which are composed of 
toxic metals.22 
1.3.1 Magnetic Iron Oxide Nanoparticles 
Theoretically, magnetic iron oxide nanoparticles can be guided via an external magnetic field to 
the site of interest. Among many examples, Carenza et al. evaluated the guidance of magnetic 
iron oxide nanoparticles to the brain using an external magnet for neurorepair therapy.13  To date, 
these nanovectors have widely been explored for use as contrast agents for imaging modalities 
such as computed tomography (CT), positron emission tomography (PET), and magnetic 
resonance imaging (MRI) as they present increased sensitivity and short acquisition time, 
allowing for the production of high resolution images.23-25 In fact, Ferumoxytol (an FDA-
approved magnetite-based product used to treat iron deficient patients) has been clinically tested 
for its use as an MRI contrast agent for imaging of the liver.26 
 Of the many iron oxides available, magnetite (Fe3O4) has received considerable attention for 
biomedical applications due to its biocompatibility and biodegradability.27 Many reviews have 
been published in literature outlining various synthesis methods, coatings, and applications of 
magnetic nanoparticles.27-29 Several methods have been developed to synthesize Fe3O4 
nanoparticles. These synthesis methods can be categorized into physical methods, wet chemical 
methods, and microbial methods.27 Table 1.1 lists common examples of synthesis techniques for 
each category, and the advantages and disadvantages outlined by each. 
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Table 1.1: Common synthesis methods for iron oxide nanoparticles27, 29 
Category Techniques Advantages Disadvantages 
Physical 
Electron beam 
lithography 
Easily change/optimize patterns using 
CAD software Poor control of particle size 
down to the nm scale Gas-phase 
deposition 
Results in 1-dimensional iron oxide 
nanostructures 
Wet 
chemical 
Chemical co-
precipitation 
Mild reaction conditions, very simple, 
cheap chemicals 
Difficult to control size and 
oxidation 
Hydrothermal 
reaction 
Narrow size distribution, tunable 
magnetism, controllable shape and 
crystallinity 
High temperature, and toxic 
organic compounds required 
Thermal 
deposition 
Tunable magnetism and size, good 
crystallinity 
High temperature and 
pressure required 
Microbial Microbial Processes 
High yield, good reproducibility, 
required low temperature and energy 
Process takes from several 
days up to 3 weeks 
Also, for biomedical applications, it is desirable to coat the nanoparticle surface in order to 
produce biocompatible nanoparticles with chemically reactive groups for additional 
functionalization.25 Nanoparticles can be coated with an organic coating using biocompatible 
polymers and functionalized through hydrophobic interactions or covalent bonds such as amides. 
Inorganic coatings such as silica can also be used to surround the nanoparticle core in a core-
shell structure.  In fact, these surface coatings play a crucial role in the toxicity and in vivo fate of 
the iron oxide nanoparticles as reported by Feng et al.30 Uncoated iron oxide nanoparticles 
caused hepatic, renal, and splenic disturbances, specifically in terms of renal toxicity, compared 
to coated nanoparticles. However, these disturbances can be reversed, particularly in coated 
nanoparticles after excretion, which was attributed to the recovery process observed 48 hours 
after administration. Furthermore, uncoated iron oxide nanoparticles tend to gather in biological 
fluids resulting in their rapid clearance from the body.31 In comparison, coated iron oxide 
nanoparticles, specifically 10 – 100 nm in size, offer a long circulation time in the body. In 
addition, the surface chemistry of the particles plays an important role in their uptake by the liver 
and spleen. Feng et al. studied the fate of dextran-coated iron oxide nanoparticles and found that 
70% of the dextran was found in the urine within 24 hours of administration, and 30% was 
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retained over a period of a few days.30 Eventually, these particles are eliminated through the 
excretory system.  
1.4 Thesis Objectives and Hypothesis 
The objective of this thesis project was to develop coated magnetic iron oxide nanoparticles for 
the targeted and sustained delivery of curcumin to cancerous cells. In addition, the development 
of folate-labeled magnetic nanoparticles for their selective uptake by cancer cells was 
investigated. The central hypothesis of this thesis is that coated magnetic nanoparticles will 
increase the bioavailability of curcumin to cancer cells, and sustained release will be achieved 
depending on the amounts and ratios of molecules used to coat the magnetic core. Furthermore, 
folate-labeling will enhance the uptake of nanoparticles by cancer cells. The magnetic properties 
of the iron oxide core, along with the selective targeting of the folate ligand is intended to serve 
as a dual targeting system to destroy cancer cells, meanwhile rendering healthy tissue unharmed.  
1.5 Thesis Outline 
We proposed a dual targeting drug delivery system for the sustained delivery of curcumin to 
cancer cells. Magnetite (Fe3O4) nanoparticles were synthesized via a simple precipitation method 
using only one iron salt, and simultaneously coated with β-cylcodextrin (β-CD) and poly 
(propylene glycol) bis (2-aminopropyl ether) (PPG-NH2) during the synthesis process. β-CD is 
an FDA approved cyclic molecule composed of seven sugar units, which was used for curcumin 
encapsulation. PPG-NH2 is a poly(propylene glycol) with functional amines on both ends of the 
molecule. This poly(propylene glycol) derivative was chosen due to its hydrophobic properties 
allowing it to be trapped within the β-CD core.32,33 Folic acid will be attached to PPG-NH2 
through an amide bond in order to selectively target the folate receptor which is overexpressed 
on the surface of cancer cells.  With the magnetic properties of iron oxide potentially allowing 
magnet-induced guidance to tumour sites, along with the selective targeting of the folate ligand, 
this dual targeting system was designed for the destruction of cancer cells without affecting 
healthy tissue. Synthesized magnetite nanoparticles containing different ratios of β-CD:PPG-NH2 
were characterized using different techniques and tested for their ability to sustain curcumin 
release. Chapter 2 gives a detailed description of the chemical properties of curcumin, along with 
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its bioactivity for cancer treatment, and previous delivery approaches. The research results of this 
thesis are described in detail in Chapter 3.  
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Chapter 2  
2 Curcumin, a Promising Anti-cancer Therapeutic 
2.1 Introduction 
For the past few decades there has been rapid growth in the interest of using natural products for 
therapeutic applications. Although this idea seems recent, our ancestors frequently used natural 
compounds to combat illness. The development of synthetic pharmaceuticals revolutionized 
modern medicine over the last century, but the undesirable properties and side effects of these 
drugs has inspired a search for natural approaches to disease prevention and treatment with the 
hope that naturally occurring compounds may be better tolerated than their synthetic 
counterparts. Of particular interest is curcumin, the principal active ingredient in the traditional 
dietary spice turmeric, responsible for its colour, taste, and most of its chemical and biological 
properties. Curcumin is derived from Curcuma longa, a plant of the ginger family. The other two 
curcuminoids present in turmeric in lower concentrations are demethoxycurcumin, and bis-
demethoxycurcumin.  
While curcumin gained immense attention as a medicinal drug in modern medical applications 
only a few decades ago, it has been used for hundreds of years in some areas of the world. In 
Asia, specifically India and China, turmeric has been used as a drug for more than two thousand 
years.1 Ayurveda, an ancient medicinal system practiced in India, incorporated the use of natural 
herbs to treat various illnesses. Amongst the commonly used herbs, turmeric was used most 
abundantly due to the medical effects of curcumin. In the traditional Ayurvedic approach, 
turmeric was crushed into a paste for the treatment of eye infections, burns, bug bites, and any 
skin related diseases. Furthermore, new mothers in India are given a drink containing turmeric 
paste, honey, ginger, and milk to drink daily following child birth.1 Turmeric is also used in 
different forms to cure cough and respiratory complications, along with dental diseases, 
flatulence, and indigestion. Curcumin was also used as a medicine in ancient Polynesian culture. 
It has been noted in historical documents that the Polynesian people carried turmeric with them 
during long voyages to Hawaii.2 Today, Hawaiians utilize curcumin for various medicinal 
purposes. It is known to them as Olena. 
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Curcumin was not introduced to Western cultures until the 14th century when European explorers 
were introduced to Asian countries. In particular, Marco Polo was introduced to curcumin during 
his visit to the Asian continent in 1280 AD.2, 3 It was noted in his writings that the native people 
of India and China used a vegetable that contained all the properties of saffron, but this spice was 
not quite saffron. In addition, the Portuguese sailor, Vasco de Gama, sailed to India 
approximately 500 years ago specifically in search of spices for their medicinal use.4 It was not 
until his return to Europe that curcumin was truly introduced into Western cultures. Despite 
curcumin’s extensive history, scientists were not able to isolate the curcumin molecule until the 
1800s. In 1870, scientists obtained the crystalline form of curcumin, and elucidated its overall 
structure in 1910.3 Its chemical structure is responsible for its unique physicochemical and 
biological properties.  
2.2 Physicochemical Properties 
Curcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, is a hydrophobic 
polyphenol. It is a golden-yellow solid, with a molecular weight of 368 g/mol and a melting 
point of 183 °C. It is often used as a dye owing to its vibrant colour. As shown in Figure 2.1, 
curcumin can exist in different tautomeric forms. The aromatic rings are functionalized with 
methoxy and hydroxy groups in an ortho position with respect to one another. The aromatic rings 
are connected to one another via a seven-carbon spacer that contains two α,β-unsaturated 
carbonyl groups. As a result of this structure, a beta-diketone and equilibrating keto-enol 
tautomeric forms of curcumin are possible.5 
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Figure 2.1: Tautomeric forms of curcumin 
2.2.1 Effect of pH 
Among the factors that affect the properties of curcumin is pH. Although curcumin has been 
shown by X-ray diffraction analysis to exist in the keto-enol form in the solid state,6 there has 
been controversy concerning whether curcumin exists in its beta-diketo or keto-enol form at 
neutral and slightly acidic pH.5 For example, Jovanovic et al. have proposed that the beta-
diketone form of curcumin predominates in mildly acidic aqueous solution and in cell 
membranes.7 They have also suggested that the central methylene group of the diketone form can 
act as a potent hydrogen atom donor in radical reactions, potentially mediating its biological 
activity. However, Payton et al. have recently performed detailed NMR studies supporting that 
curcumin exists as keto-enol tautomers in a range of hydrophobic and hydrophilic solvents, over 
a pH range from 3-9.5 These results are in agreement with density functional theory calculations 
by Shen and Li,8 which correlated the calculated absorption wavelength and oscillator strength of 
curcumin with the experimental values, supporting the predominance of the keto-enol tautomers. 
The keto-enol form was calculated to be more stable than the diketone form by 7.75 kcal/mol. 
This was attributed to the planar structure of the enol form, allowing for resonance stabilization 
to occur, while that of the ketone form was twisted.  
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As shown in Figure 2.2, at pH less than 1, a protonated form of curcumin is observed and the 
molecule can adopt a fully conjugated protonated form.9 Figure 2.2 also illustrates the proposed 
deprotonated forms of curcumin that can occur as the pH is increased.9 As a consequence of 
deprotonation, curcumin exhibits increased aqueous solubility in alkaline solutions while it is 
practically insoluble in water at acidic and neutral pH. However, curcumin has been 
demonstrated to undergo degradation under alkaline conditions, as demonstrated by Tonnesen et 
al. and Wang et al.9, 10 
 
Figure 2.2: Proposed structure of curcumin in (a) acidic, (b) neutral, and (c) basic 
environments 
2.2.2 Effect of Temperature 
Solid curcumin is generally stored at -20°C, though there is no evidence that curcumin is not 
stable at somewhat higher temperatures. Wang et al. studied the stability of curcumin at body 
temperature.10 In this study, curcumin was incubated under various physiological conditions at 
37 °C to measure its stability. Curcumin was incubated in 0.1 M phosphate buffer solution, 
culture medium, culture medium with 10% serum, and human blood. Samples were analyzed by 
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high performance liquid chromatography (HPLC) after one, four, and eight hours of incubation. 
It was noted that the rate of curcumin degradation was dependent on the conditions. When no 
serum was present, curcumin underwent degradation more rapidly than in the medium with 
serum or in human blood. This difference was accounted for by the stabilization of curcumin by 
the serum and it was suggested that care must be taken in the manipulation of curcumin under 
serum-free conditions, particularly in the interpretation of the results of biological studies, where 
the presence of degradation products such as vanillin should be taken into account.  
In another study, Gopinath et al. investigated curcumin incorporated collagen films (CICFs) for 
dermal wound healing.11 CICFs were prepared by dissolving a weighed amount of curcumin in 
ethanol, and mixing this solution with 50 mL of collagen/acetic acid solution at 4°C for 24 hours. 
Micro-shrinkage temperature measurements were carried out on both CICF and pure collagen. It 
was found that without curcumin, the shrinkage temperature of collagen was 55°C, which was 
increased to 78°C when curcumin was incorporated in the collagen. It was concluded from this 
finding that curcumin increases the thermal stability of collagen. This group previously reported 
that quercetin also increased the thermal stability of collagen, allowing them to draw the 
conclusion that polyphenols are generally capable of enhancing the temperature stability of 
collagen and matrices of different types.  
Previous studies have demonstrated that natural phenolic compounds suffer from biodegradation, 
change of structure, and loss of biological activity when heated. Based on this, Liu et al. set out 
to investigate the thermal stability of curcumin.12 Specifically, the relationship between the pre-
incubation temperature of curcumin and its inhibitory effect on amyloid fibrillation of hen egg-
white lysozyme (HEWL) was studied. Unmodified HEWL was used as a control agent, along 
with HEWL modified with curcumin pre-incubated at 10, 25, 40, 55, and 70°C for 329 hours. 
The result of the Thioflavin T (ThT) fluorescence assay is shown in Figure 3, where a decrease 
in fluorescence corresponds to a decrease in amyloids.  
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Figure 2.3: ThT assay results, showing that the ability of curcumin to inhibit the amyloid 
fibrillation of HEWL (inhibition is detected as a decrease in fluorescence intensity). 
Reprinted from reference 12 with permission from Elsevier 
As shown in Figure 2.3, the unmodified HEWL exhibited the highest amyloid content, and the 
HEWL sample modified with curcumin pre-incubated at 70°C provided similar results. This can 
be attributed to the lack of biologically active curcumin following incubation at this temperature. 
However, at a pre-incubation temperature of 55°C, it was evident that not all of the curcumin 
degraded, as the fluorescence decreased by approximately 50%. Therefore, a clear dependence of 
curcumin stability on temperature was observed. This trend was further verified using 
transmission electron microscopy (TEM), where the images clearly illustrated the presence of 
high amounts of amyloid fibrils in the unmodified HEWL, and that modified with curcumin pre-
incubated at 70°C. However, the samples containing curcumin pre-incubated at lower 
temperatures exhibited fewer amyloid fibrils, with the amount decreasing with decreasing pre-
incubation temperature. Similar results were obtained in the cell viability study, leading the 
authors to conclude that curcumin is most stable in the temperature range of 10-55°C and 
degraded almost completely at 70°C within 24 hours.  
17 
 
Thus, it can be generally concluded that curcumin is most stable at low temperatures; however, 
its stability is still maintained at room temperature and physiological temperature, allowing it to 
be used in medical applications. At very high temperatures however, curcumin degrades into 
different products, which will be discussed briefly below.  
2.2.3 Degradation Products of Curcumin 
Under certain conditions curcumin becomes unstable, as previously discussed, and degrades, 
yielding other compounds. The three degradation products often found are vanillin, ferulic acid, 
and feruloylmethane.13 In the previously described study by Wang et al. it was noted that when 
curcumin degraded in different media, the resulting degradation products were characterized by 
HPLC-mass spectrometry to be vanillin, ferulic acid, and feruloylmethane.10 However, in this 
study there was also an unknown product present in larger amounts. It was hypothesized that this 
product was trans-6-(4'-hydroxy-3'-methoxyphenyl)-2, 4-dioxo-5-hexenal. 
 
Figure 2.4: Proposed degradation products of curcumin 
A study conducted by Schieffer investigated the degradation products of curcumin obtained after 
exposure to light.14 Curcumin is extremely sensitive to light and undergoes degradation in its 
presence. The study concluded that curcumin underwent photolytic degradation to produce 
several products with the most abundant being p-hydroxybenzaldehyde, vanillic acid, vanillin, 
and ferulic acid.  The difference in some of the products proposed in this study versus those 
obtained by Wang et al. suggests that the thermal and photochemical degradation pathways of 
curcumin may be different, though it is generally agreed that the degradation of curcumin is 
much more rapid in the presence of light.  
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Singh et al. explored the photodegradation of curcumin in the presence of a TiO2catalyst.15 It was 
reported that curcumin formed a complex with TiO2, which was evidenced by the presence of a 
broad, red-shifted absorption band. Photodegradation was carried out in two solvent media, 
water-methanol and water-acetonitrile, and the degradation products were evaluated using gas 
chromatography. The results were similar for both media, with the predominant degradation 
product being vanillin, along with minimal amounts of CO2, 4-hydroxybenzaldehyde, and 
methoxyvanillin.  
It is widely proposed that vanillin and ferulic acid are the major degradation products and in fact 
contribute to the therapeutic effects of curcumin. In fact, there is a variety of work concerning 
the therapeutic effects of vanillin.13, 16-18 Despite the potential therapeutic effects of vanillin, the 
recent work of Wang et al. outlined above,10 casts doubt on the proposition that vanillin is in fact 
a major degradation product of curcumin. In the case of this study, vanillin and ferulic acid were 
only minor degradation products, and there existed a major degradation product with currently 
unconfirmed identity.  
Gordon and Schneider, and Griesser et al. also performed similar degradation reactions in order 
to challenge the belief that vanillin, ferulic acid, and feruloylmethane are the major degradation 
products of curcumin.19, 20 The results obtained using HPLC suggested the presence of one major 
product, while vanillin, ferulic acid, and feruloylmethane were close to undetectable. Further 
analysis revealed a molecular weight of 400 g/mol, indicating insertion of oxygen to curcumin. 
Based on 1D and 2D homo- and heteronuclear NMR experiments, the unknown compound was 
identified as a bicyclopentadione form of curcumin.19 Figure 2.5 illustrates the proposed 
autoxidation mechanism leading to this product. It was proposed that this degradation 
mechanism accounts for curcumin’s antioxidant properties, and not the alternative degradation 
products.  
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Figure 2.5: Proposed mechanism for the autoxidation of curcumin19 
Ketron et al. also investigated the oxidative properties of the bicyclopentadione form of 
curcumin, exploring its effects on human type II topoisomerases.21 A series of experiments were 
performed to evaluate the effect of the bicyclopentadione form of curcumin, stable curcumin, 
vanillin, ferulic acid, and feruloylmethane on the human enzymes. The results revealed that the 
bicyclopentadione form of curcumin poisons human topoisomerases, in contrast to curcumin and 
its three fragmentation products, which did not reveal a significant effect. Thus, while vanillin, 
ferulic acid, and feruloylmethane may exhibit therapeutic effects, it still remains to be confirmed 
which therapeutic effects of curcumin arise from the parent molecule, and which arise from the 
various possible degradation products. 
2.3 Effect of Curcumin on Cancer Cells 
Although curcumin has been used as a traditional medicine to treat several conditions including 
inflammation, respiratory infection, and blood clogging, there is rapidly growing interest in its 
effects on cancer. The motivation for the use of curcumin arises not only from its potential 
therapeutic effects, but also from the knowledge that it may be better tolerated by patients, in 
comparison with most chemotherapeutic drugs that suffer from numerous harmful side effects 
such as nausea and vomiting, diarrhea, hair loss,22 and more serious long term conditions such as 
liver failure.23 Several studies comparing the incidences of cancer and cancer related deaths in 
India and the West revealed lower risk of cancer in India (Table 2.1).24 It is proposed that one of 
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the major reasons for the drastic difference in cancer occurrences in these regions is the 
increased intake of dietary agents such as curcumin, and other plant derivatives in Asia.   
Table 2.1: Comparison of incidences and deaths in India and United States for common 
cancers showing cases per 1 million persons24 
Cancer 
USA India 
Cases Deaths Cases Deaths 
Lung 660 580 38 37 
Breast 660 160 79 41 
Prostate 690 130 20 9 
Colon/rectum 530 220 30 18 
Bladdar 202 43 15 11 
Thyroid 55 5 12 3 
Leukemia 100 70 19 17 
Why does curcumin possess anti-cancer properties? Generally, cancer with its diverse origins has 
several molecular markers involved in its onset and progression. Curcumin is capable of 
interfering with several biochemical pathways involved in the proliferation and survival of 
cancer cells by directly and indirectly binding to different targets. Curcumin has been shown to 
interact with various targets including transcription factors, growth factors, DNA, RNA, and 
several proteins that are involved in cell signal transduction pathways.25, 26 There are several 
features of curcumin's chemical structure that make it a favourable and versatile binding partner 
for a wide variety of molecular targets (Figure 2.6). For example, curcumin possesses two 
hydrophobic phenyl groups connected by a relatively flexible linker. This allows the molecule to 
assume different conformations that can maximize pi-pi and van der Waals interactions with 
aromatic and other hydrophobic amino acid residues of proteins. The phenolic hydroxyl and 
methoxy groups, as well as the ketone and enol groups present on the ends and in the middle of 
the molecule respectively can participate in strong and directed hydrogen-bonding interactions. 
The possibility for keto-enol tautomerism introduces additional functionality, with the possibility 
to arrange donor and acceptor groups for hydrogen bonding in multiple ways. Furthermore, the 
 α,β-unsaturated ketone moiety can serve as a Michael acceptor for nucleophilic attack by the 
thiol moieties of cysteine residues or the Se
by which curcumin exhibits anti-
reviews25-29 and some of these mechanisms are described below. 
Figure 2.6: Structural features of curcumin involved in binding to protein targets
Curcumin’s mechanism of action can occur both intrinsically (mitochondrial) and extrinsically 
(mediated via cell surface transmembrane death receptors).
initiated by activation of tumour suppressor p53 (p53), which is a cell cycle regulator, as well as 
through members of the B-cell lymphoma 2 (Bcl
homologous antagonist killer (Bak) and Bcl
apoptotic members of the Bcl-2 family. Bak and Bax promote apoptosis by forming pores in the 
mitochondrial membrane releasing cytochrome c into the cytoplasm, thereby activating a caspase 
cascade.30 Curcumin is capable of 
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the mitochondrial membrane potential and activating caspase-3 and -9 at concentrations of 0 – 30 
µM.  
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor involved in the primary 
defense pathway against the effects of oxidative stress.33-35 Under normal conditions, Nrf2 is 
located in the cytoplasm with its activity suppressed by the chaperon protein Kelch like-ECH-
associated protein 1 (Keap1). Under conditions of oxidative stress, which alter the thiol groups 
on Keap 1, the Nrf2-Keap1 interaction is disturbed, causing Nrf2 to be transported to the nucleus 
where it binds to the anti-oxidative response element (ARE)and activates the transcription of 
genes encoding for detoxifying enzymes such as hemeoxygenase-1 (HO-1), which protect 
against various forms of stress.36 It has been proposed that Michael addition of curcumin to thiols 
on Keap1 may result in a conformational change that disrupts the Nrf2-Keap1 complex, 
promoting Nrf2 binding to AREs, but this still requires structural verification.28 
Another transcription factor commonly studied as a target for cancer treatment is nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB). This transcription factor is involved in 
cell response to free radicals, cytokines, ultraviolet radiation, and viral or bacterial antigens. 
Because NF-κB is present in the cytoplasm in an inactive form until stimulated, it is considered a 
first responder transcription factor as it does not require synthesis for activation. Upon 
stimulation, NF-κB is translocated to the nucleus triggering the expression of certain genes that 
suppress apoptosis and promote proliferation and metastasis. 
In the work of Youns et al. the effects of curcumin were studied on human pancreatic cell lines 
expressing different levels of cyclooxygenase-2 (COX-2), an enzyme that plays an important 
role in response to inflammation.37 Curcumin was capable of inhibiting proliferation and 
inducing apoptosis through the extrinsic pathway mediated through tumour necrosis factor 
(TNF) receptor activation. The TNF pathway triggers caspase-8 and -3 activation, which are pro-
apoptotic, but also induces NF-κB, which regulates the expression of the COX-2 gene. Curcumin 
also resulted in down-regulation of COX-2, suggesting the suppression of NF-κB activation. 
Using molecular docking studies, curcumin has been shown to bind to TNF-α through various 
van der Waals and hydrogen bonding interactions, which may inhibit the binding of TNF-α to its 
receptor, thus preventing the activation of NF-κB.38 
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In another study, curcumin’s ability to chemosensitize breast cancer cells to 5-fluorouracil was 
investigated.39 5-Fluorouracil has been noted to up-regulate the NF-κB pathway inducing the 
expression of its regulated genes, leading to chemoresistance. IκB kinase (IKK) is a signal-
induced enzyme, which phosphorylates IκBα, an NF-κB inhibitory protein. Upon 
phosphorylation, IκBα is detached from NF-κB, leaving NF-κB free to translocate to the nucleus 
and induce the expression of different genes. The authors showed that curcumin inhibited the 
phosphorylation of IκBα by IKK, preventing the dissociation of IκBα from NF-κB, keeping NF-
κB dormant. As a result, chemoresistance towards 5-fluorouracil treatment was significantly 
decreased. 
Activated protein-1 (AP-1), composed of Jun, FOS, and ATF protein dimers,40 is another 
transcription factor commonly used as a target for cancer treatment as it is responsible for 
differentiation, proliferation, apoptosis, and oncogenic transformations.41 Activation of AP-1 by 
stimuli such as growth factors, bacterial/viral infections, cytokines, stress signals, or oncogenic 
factors promotes the binding of AP-1 to the TPA responsive element (TRE) causing the 
expression of several genes such as cyclin-D1, MMP, VEGF, and uPA, some of which mirror 
genes activated by NF-κB and are involved in the angiogenesis and growth of cancer cells.24 
Curcumin has been proposed to inhibit this pathway via direct interaction with the AP-1 DNA-
binding site.42 Spectroscopic evidence has shown that curcumin can in general bind to DNA 
through O2 of thymine in the minor groove, N7 of guanine and adenine in the major groove and 
to the backbone phosphate moieties with a binding constant of 4.3 × 104 M-1.43 
Curcumin was shown to suppress binding of AP-1 to DNA in human leukemia cells,44 and 
transformed keratinocytes.45 Furthermore, curcumin possesses cytotoxic activities towards 
human papillomavirus (HPV)-16 and HPV-18 infected cells associated with the development of 
cervical cancer, in addition to promotion of cervical cancer cell apoptosis, and inhibition of AP-
1-DNA binding, thereby preventing HPV gene expression.46 The down regulation of AP-1 by 
curcumin has also been reported for prostate cancer.47,48 It was reported that exogenous hydrogen 
peroxide induces prostate cancer LNCaP cell proliferation via activation of AP-1 and consequent 
stimulation of heparin affin regulatory peptide (HARP) gene.49 This cascade is halted by 
curcumin inhibition of the hydrogen peroxide induced HARP expression.  
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The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway 
is another cascade noted to be involved in the progression of cancer.50 JAK belongs to the non-
protein receptor tyrosine kinase family, and STATs are latent cytoplasmic transcription factors. 
The JAK/STAT pathway plays a role in immune response, mediating interactions of cytokines, 
hormones, and growth factors and their respective receptors. Upon binding of a ligand to its 
receptor, JAK is activated and the increased kinase activity induces phosphorylation of tyrosine 
residues on the receptor. Tyrosine phosphorylation creates phosphotyrosine sites on the receptor, 
which STATs are capable of binding to. The STATs recruited to these binding sites are 
themselves phosphorylated, creating phosphotyrosine sites for other STATs, thereby creating 
dimers. STAT dimers accumulate in the nucleus and activate their target genes. Kroon et al. 
studied the effect of this pathway on prostate cancer cells, specifically with respect to STAT3 
which of the seven known STAT proteins has been reported to be closely associated to a variety 
of human cancers.51 
Yang et al. investigated the effect of curcumin on the JAK/STAT signaling pathway in small 
lung cancer cells.52 The authors reported that curcumin was capable of suppressing cell 
proliferation and migration through inhibition of STAT3 phosphorylation, thus suppressing 
downstream target genes. To further ensure the role of this cascade on the cancer cells, the 
authors showed that activation of STAT3 induced by interleukin-6 (IL-6), a pro-inflammatory 
cytokine, lead to increased proliferation and cell survival. These results supported the conclusion 
that this pathway can be a potential target for cancer treatment with curcumin. Comparable 
results were demonstrated earlier on glioblastomas by Weissenberger et al. in 2010.53 
In addition to the above, other molecular signaling pathways reported to be associated with 
cancer cell proliferation have also been studied in the context of curcumin. The effect of 
curcumin on both the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian 
target of rapamycin (mTOR) pathway and the mitogen-activated protein kinases (MAPK) 
pathway has been investigated by Ono et al.54 PI3K, a family of enzymes involved in cell 
growth, survival, and proliferation, are activated via ligand/receptor interactions where they are 
recruited to the inner cell membrane. PI3K activates AKT, which in turn activates mTOR 
through direct phosphorylation, promoting cell survival.55 MAPK are activated by a series of 
phosphorylation cycles in response to a variety of stimuli. The authors were able to demonstrate 
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that curcumin inhibited the phosphorylation of mTOR by AKT, suppressing its downstream 
targets and inducing apoptosis. Interestingly, curcumin enhanced MAPK activity. Specifically, 
ERK1/2, a subgroup of MAPK, activation by curcumin promoted apoptosis in colorectal 
carcinoma cells. As determined by Western blotting, both pathways were associated with G2/M 
phase arrest, and poly (ADP-ribose) polymerase (PARP) cleavage, which is characteristic of 
cells undergoing apoptosis.  
The exportin 1 (CRM1)-dependent nuclear export pathway is a less commonly investigated 
cascade. CRM-1 facilitates the transport of large molecules across the nuclear membrane to the 
cytoplasm.56 Furthermore, the structure of CRM1 allows the binding of Ran protein bound to 
GTP promoting the binding of different cargo proteins to CRM1 in response to a nuclear export 
signal (NES). Nui et al. showed that curcumin targets CRM1 through the Michael addition 
reaction of the α,β-unsaturated carbonyl of curcumin and the nucleophilic Cys528of CRM1.57 
Mass spectrometry revealed that curcumin bound directly to a CRM1-derived peptide containing 
the Cys528 moiety, making it capable of arresting this cascade. Furthermore, the authors 
investigated the effect of curcumin on cargo proteins, as many cancer-promoting proteins are 
trafficked by CRM1. It was found that curcumin treatment caused the up-regulation of tumour 
suppressor cargo proteins p73 and p27, and a down-regulation of the pro-survival COX-2 and 
Cyclin D1.  
In other work, the TNF-related apoptosis-inducing ligand (TRAIL) pathway and its enhancement 
by curcumin has been investigated.58 TRAIL is a protein that acts as a ligand, binding to death 
receptor (DR)-4 and -5, to activate caspase-8. Caspase-8 cascade activates procaspase-3, -6, and 
-7 downstream to induce apoptosis. It was reported that breast cancer cells pre-incubated with 
curcumin became sensitized to TRAIL, promoting cell death.58 However, the enhancement of 
TRAIL sensitization was cell-type dependent, with the extent of sensitization differing from one 
breast cancer cell line to another.  
Steroid receptors such as estrogen receptors (ER), progesterone receptors (PR), and androgen 
receptors (AR) function as transcription factors, regulating their respective target genes. 
Abnormal expression of steroid receptors’ transcription coregulators causes the deviation away 
from their normal functions, thereby participating in the onset and progression of cancers.59 For 
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this reason, anti-steroid receptor compounds are used clinically to treat cancer due to their 
apoptosis-inducing properties.  
Curcumin analogues were shown to behave as androgen receptor antagonists in human prostate 
cancer as studied by Ohtsu et al.60 Curcumin was identified as a binding ligand for the nuclear 
vitamin D receptor (VDR) correlated with human colon cancer, playing a role in cancer 
chemoprevention.61 In particular, curcumin was capable of competing with 1,25-
dihydroxyvitamin D3 (1,25D) for the direct binding to VDR. Occupation of the VDR binding site 
by curcumin caused conformational changes to the receptor, transforming it to its 
transcriptionally active form, thereby inducing the expression of tumour suppressor genes. 
Moreover, the use of curcumin in breast cancer treatment showed that it can interact with breast 
cell lines expressing varying cellular receptor phenotypes involved in breast cancer, thus 
inducing anti-proliferative effects.62,63 
In addition to anti-proliferative and apoptotic effects, curcumin possess chemosensitizing,64, 65 
radiosensitizing,64, 66 and radioprotective effects.66, 67 Furthermore, the effect of curcumin on 
newly identified pathways associated with microRNA, stem cells, and autophagy have been 
studied.26 MicroRNA are small, noncoding RNAs that negatively regulate the expression of 
genes by binding to the 3' region of the untranslated target mRNA, thereby inhibiting translation 
or inducing mRNA degradation. Because microRNA possess both oncogenic and tumour 
suppressing properties, anti-cancer effects were achieved upon treatment with curcumin, through 
the up- and down-regulation of certain microRNA.68-70 Cancer stem cells—undifferentiated 
cancer cells that can generate tumours by self-renewal—have been shown to drive and sustain 
human cancers, and treatment with curcumin has been demonstrated to interfere with the self-
renewal of cancer stem cells.71-73 Moreover, autophagy is the catabolic or “self-eating” 
mechanism involving the sequestration of unnecessary, dysfunctional components or organelles 
into autophagosomes and their degradation in lysosomes.74 This process is altered in cancer cells, 
promoting cell survival. Curcumin was shown to trigger autophagy in pleural mesothelioma,75 
oral cell carcinoma,76 and glioma cells.77, 78 With the many molecular targets of curcumin, indeed 
it can serve as a potential therapeutic for the destruction of cancer cells.  
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2.4 Clinical Studies 
Thus far, more than 20 clinical trials with curcumin for various cancers including colorectal, 
pancreatic, breast, prostate, multiple myeloma, lung, head and neck, and cancer lesions have 
been completed. The results of these studies have been summarized in recent review 
articles,25,26,79 so we describe here only a few recent noteworthy examples.  
At a dose of 360 mg, three times per day, curcumin was found to increase body weight, increase 
the number of apoptotic cells, and enhance the expression of p53 in colorectal cancer patients 
after diagnosis and before surgery.80 However, the health improvement related to increase p53 
expression still needs to be studied. Curcumin was also shown to reduce the formation of 
aberrant crypt foci (ACF), the precursor of colorectal polyps, in smokers at a dose of 4 g/day, 
suggesting a potential cancer chemopreventive role for curcumin.81 A recent study demonstrated 
that following doses of 2.35 g/day for 14 days prior to biopsy or colonic resection, curcuminoids 
were detectable in colonic tissue, mucosa and urine of most patients, with minimal side effects 
observed.82 The efficacy of curcumin in combination with gemcitabine against advanced 
pancreatic cancer was also recently evaluated in two different trials.83,84 Kanai et al. found that 
curcumin at a 8 g/day in combination with gemcitabine was safe and well-tolerated.84 However, 
Epelbaum and coworkers found that some patients experienced abdominal pain at this dose, and 
did not obtain a highly promising therapeutic response.83 Curcumin in combination with 
docetaxel in patients with advanced and metastatic breast cancer was also recently studied in a 
Phase 1 trial.85 It was found that the maximum tolerable dose of curcumin was 8 g/day and in 
combination with the standard dose of docetaxel, the recommended dose was 6 g/day for seven 
consecutive days every three weeks. The safety, tolerability, and efficacy of curcumin in patients 
with asymptomatic, relapsed, or plateau phase multiple myeloma has also evaluated by Vadhan-
Raj et al.86 At doses of 4 to 8 g/day for a year, curcumin was found to down-regulate the 
activation of NF-κB and STAT3, and suppress COX-2 expression, but further studies are 
required to demonstrate efficacy against multiple myeloma. In patients with familial 
ademonmatous polyposis, curcumin was reported to provide improvements in patients with 
precancerous lesions at a dose of 12 g/day (0.5% curcumin).87 
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Based on a search of www.clinicaltrials.gov, there are currently more than 15 clinical trials 
ongoing for the treatment of various cancers with curcumin. Curcumin is approved by the United 
States Food and Drug Administration as being generally regarded as safe (GRAS). It is marketed 
in various forms as a dietary supplement in many countries. However, there is not yet an 
approved drug license for curcumin. This can likely be attributed in part to the multi-targeting 
property of curcumin.88 It also results from the extremely poor solubility in aqueous media and 
very low bioavailability of curcumin.89, 90 The next section of the review discusses potential 
means of increasing the solubility and bioavailability of curcumin in order for the drug to make 
the transition from the lab into clinical use.  
2.5 Enhancement of Curcumin Solubility and Bioavailability 
Curcumin has been reported to be safe at doses up to 12 g/day.91-93 However, because curcumin 
undergoes rapid metabolism and clearance when administered, it has very poor bioavailability.94 
A study demonstrated that when curcumin was administered orally to rats at a dose of 500 
mg/kg, a peak concentration of 1.8 ng/mL was detected in the plasma, while curcumin given 
intravenously showed no trace of the drug in plasma within 1 hour of administration.95 In another 
study, an intraperitoneal injection of 0.1 g/kg in mice showed a plasma concentration of 2.25 
µg/mL after 15 minutes of administration, with concentrations of 177.04, 26.06, 26.9, and 7.51 
µg/mL in the intestines, spleen, liver, and kidneys, respectively.96 A human study revealed that a 
total oral dose of 3.6 g/day of curcumin resulted in nanomolar amounts of curcumin in plasma 
samples on day one at the 1 hour mark, with similar amounts on day 2, 8, and 29.97 How can the 
bioavailability of curcumin be enhanced knowing that concentrations of at least 10-5 – 10-4 M are 
required for the drug to have any therapeutic impact?95 One approach can involve the co-
administration of adjuvants that can block the metabolic processing of curcumin. For example, 
the co-administration of curcumin and piperine, a known inhibitor of intestinal and hepatic 
glucuronidase, involved in curcumin glucuronidation, was shown to increase the bioavailability 
of curcumin by 2000%.98 There has also been ongoing research on drug delivery systems that 
may be used to transport curcumin to the desired site, or simply enhance its solubility.  
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2.5.1 Preparation of Curcumin Co-crystals 
A promising approach to solubility enhancement is the development of co-crystals. Co-crystals 
are a class of solid drugs formed using an active pharmaceutical ingredient (API), and a 
solubilizing agent.99 The resulting co-crystals generally possess enhanced physicochemical 
properties such as solubility and stability, due to increased hydrogen bonds in the system.93 
Sanphui and coworkers studied co-crystals synthesized using curcumin as the API with two 
different solubilizing agents, resorcinol and pyrogallol (Figure 2.7), by a liquid-assisted grinding 
method.93 The melting point of the co-crystals was reported to be between that of pure curcumin 
and the solubilizing agent, with curcumin-pyrogallol having a lower melting point than 
curcumin-resorcinol. Curcumin-resorcinol co-crystals exhibited a dissolution rate 5-fold that of 
curcumin alone, while curcumin-pyrogallol co-crystals had a dissolution rate 12-fold higher than 
that of curcumin.  
 
Figure 2.7: Common coformers used with curcumin to produce cocrystals 
In another study, curcumin co-crystals were synthesized with five different coformers including 
nicotinamide, ferulic acid, hydroquinone, p-hydroxybenzoic acid, and L-tartaric acid (Figure 
2.7).90 All five co-crystal solids were noted to be eutectic, having lower melting points than both 
constituents alone, and dissolved faster than pure curcumin, with curcumin-nicotinamide having 
the fastest dissolution rate. Undoubtedly, curcumin co-crystals can serve as a solution to increase 
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the bioavailability of curcumin when administered orally. With the wide variety of coformers 
such as therapeutic drugs, salts, or even natural spices, that can be used, curcumin co-crystals can 
potentially be synthesized to treat several conditions.  
2.5.2 Delivery Systems for Curcumin 
Alternative to co-crystals, which simply enhance the dissolution rate of the drug, methods have 
been developed to transport curcumin throughout the body to the desired sites for therapeutic 
applications. A variety of nano-vehicles including liposomes, exosomes, micelles, nanoparticles, 
and dendrimers have been used to encapsulate and deliver curcumin, resulting in enhanced water 
solubility, stability and bioactivity (Figure 2.8). 
 
Figure 2.8: Curcumin-loaded drug delivery systems 
2.5.2.1 Liposomes 
Liposomes can be described as phospholipid bilayers surrounding an aqueous core, and have 
been investigated for the delivery of a wide variety of different pharmaceutical agents.100 In fact, 
lipid-based drug delivery systems are available in the clinic. One such product is Doxil, which is 
a PEGylated liposomal doxorubicin.101 Li et al. have studied the in vitro and in vivo effects of 
liposome-encapsulated curcumin on human pancreatic carcinoma cells.102 The liposomes were 
prepared from a 10:1 weight ratio of lipid (1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) and/or 1 ,2-dimyristoyl-sn-glycero-3-phosphor-rac-(1-glycerol) sodium salt (DMPG)) 
to curcumin. It was demonstrated that liposomal curcumin was capable of down-regulating NF-
κB machinery, resulting in suppressed growth and increased apoptosis of various human 
pancreatic cancer cell lines in vitro. In addition, tumour suppressive and anti-angiogenic effects 
 were observed for both BxPC-3 and MiaPaCa2 cell lines in murine models.
Saengkrit et al. investigated the cellular uptake of curcumin
bromide (DDAB)-modified liposomes compared to non
cells.103 Liposomes were prepared using various ratios of soybean lecithin, non
cholesterol and DDAB by means of the conventional thin film hydration method. The authors 
reported that cell uptake was enhanced with DDAB
cytotoxicity of these cationic liposomes was high and more work is required to optimize this
Furthermore, in vitro release studies showed that curcumin was released faster from DDAB
containing liposomes, which the authors hypothesized to be a consequence of reduced interaction 
forces between lipid chains due to the cationic charges of DDAB.
2.5.2.2 Exosomes 
An alternative to synthetic phospholipid vesicles is the naturally occurring analogue, referred to 
as exosomes. Exosomes are small, endocytic membrane vesicles that are excreted by many cells. 
They are generally formed by budding from the membrane of 
different cell types, and thus contain different protein families (Figure 
usually 30 – 100 nm in diameter and are capable of floating on sucrose gradients making them 
easy to separate from other contamin
vesicles can potentially be used for the delivery of pharmaceuticals. 
Figure 2.9: Schematic of the collection and loading of exosomes
Sun et al. studied the anti-inflammatory effects of curcumin when encapsulated in exosomes.
Curcumin was mixed at 22 °C with exosomes derived from EL
purified by sucrose gradient separation. A loading capacity of 2.9 g curcumin per 1 g
 In a recent study, 
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was reported and the solubility of curcumin was five-fold higher with exosome-entrapment in 
comparison to free curcumin. Furthermore, a stability study was conducted and it was found that 
in phosphate buffered saline at 37 °C, in the absence of exosomes, 75% of curcumin was 
degraded over 2.5 hours, while only 20% degradation was observed for exosome-encapsulated 
curcumin. An in vivo study was carried out on mice with a dose of 100 mg/kg of curcumin 
administered orally or intraperitoneally. Exosomal curcumin was present in peripheral blood at 
concentrations five to ten-fold higher than free curcumin, with no detectable amount of free 
curcumin circulating in the blood. The in vivo anti-inflammatory effects of curcumin were also 
evaluated, using a lipopolysaccharide-induced septic shock model. A significant survival 
advantage and lower cytokine levels were demonstrated for mice treated with exosomal 
curcumin in comparison with free curcumin or curcumin-free exosome and saline controls. 
2.5.2.3 Micelles 
Mohanty et al. proposed a polymeric micelle as a drug delivery system for curcumin 
encapsulation to be used for cancer therapy.106 Curcumin-containing micelles were synthesized 
using a methoxy poly(ethylene glycol) (mPEG)/poly-ε-caprolactone (PCL) formulation. The 
micelles were loaded with curcumin via a dialysis method at room temperature. The micellar 
solution was then freeze dried to obtain a dry solid form of curcumin-containing micelles. The 
authors reported a curcumin encapsulation efficiency of 60%, with a micelle size of 110 nm. The 
loaded micelles showed sustained release of curcumin lasting for one week. Furthermore, 
curcumin uptake was investigated on PANC-1 pancreatic cancer cell line using both curcumin-
loaded micelles, and unmodified curcumin for comparison. Curcumin concentrations of 10, 20, 
and 30 µM were studied. The authors observed that cell uptake of curcumin-loaded micelles at a 
concentration of 10 µM was ~3-folds higher than that of unmodified curcumin. However, at the 
highest curcumin concentration (30 µM), the micellar uptake was only ~2-folds higher than 
unmodified curcumin. This led the authors to conclude that cell uptake is more efficient at lower 
concentrations, rationalizing that at higher concentrations of curcumin-loaded micelles, 
saturation may occur, causing decreased entry of micelles into the cells. 
In another study, Podaralla et al. investigated a micellar formulation of curcumin prepared from 
mPEG conjugated to zein, a hydrophobic plant protein.107 Curcumin was encapsulated in mPEG-
zein micelles by dissolving mPEG-zein and curcumin (100:2 wt/wt) in 90% ethanol, followed by 
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dialysis to remove the remaining ethanol and free curcumin. The authors reported a micelle size 
range of 95 – 125 nm, and release of curcumin over a period of ~24 hours in vitro. The micellar 
system resulted in 1000-2000-fold enhancement in curcumin water solubility and a ~6-fold 
increase in stability, as evaluated by UV-visible spectroscopy. The uptake of curcumin-loaded 
micelles by ovarian cancer cells was 2-3-fold higher than free curcumin, leading the authors to 
conclude that this delivery system is highly promising for the delivery of anti-cancer drugs. They 
also suggested that the core or shell could potentially be modified by cross-linking in order to 
further sustain the release.  
Gao et al. studied biodegradable mPEG-poly(lactide) copolymer (mPEG-PLA) micelles for 
curcumin delivery in colon cancer therapy.108 The micelles were prepared by a self-assembly 
method, and were reported to have a narrow size distribution with an average diameter of 30 nm. 
In vitro release studies carried out in PBS containing 0.5% w/w Tween-80 at physiological 
temperature showed that free curcumin was rapidly released reaching maximum release (83%) 
within 12 hours. However, curcumin-loaded micelles showed more sustained release, reaching 
approximately 60% curcumin release in the same time period. The authors also reported 
enhanced uptake and apoptosis of colon cancer cells demonstrated by curcumin-loaded micelles 
compared to free curcumin alone. 
2.5.2.4 Nanoparticles 
Nanoparticle vehicles for the encapsulation and transportation of curcumin have also been 
developed. For example, in the formulation THERACURMIN, curcumin powder and glycerin 
was added to a solution of polysaccharides from ghatti trees, then the mixture was processed by 
wet grinding and high-pressure homogenization to produce a stable colloidal dispersion of 
nanoparticles with diameters of 190 nm.109 In clinical trials, the area under the blood 
concentration-time curve was found to be 27-fold higher for this formulation than for curcumin 
powder.109 In addition, in pancreatic or biliary tract cancer patients receiving gemcitabine no 
increase in adverse effects was observed for THERACURMIN at a curcumin dose of 200 or 
400 mg/day.110 
O'Toole et al. have used chitosan-based particles to encapsulate curcumin.111 The authors used a 
spray drying method to encapsulate curcumin inside chitosan/Tween 20 particles where the ratio 
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of chitosan/Tween 20 was varied. The particle size was noted to be 285 ± 30 nm, with a 
curcumin encapsulation efficiency of nearly 100%. In release experiments, a burst release profile 
was observed with all of the curcumin released over a period of 2 hours. While suitable for 
applications in which a rapid release of curcumin is desired, additional work may be required to 
prolong the curcumin release for some applications. 
Misra and Sahoo have co-encapsulated curcumin with doxorubicin in poly(D,L-lactide-co-
glycolide) nanoparticles.112 Doxorubicin is used to treat a variety of cancers, including leukemia; 
however, a number of cancer cells, including the chronic myeloid leukemia blasts such as K562 
cells are resistant to doxorubicin due to its sequestration into cytoplasmic vesicles and the 
induction of multi-drug resistance (MDR). Along with its other anti-cancer properties, as 
curcumin has been demonstrated to down-regulate MDR transporters, it was of particular interest 
to investigate the potential beneficial effects of incorporating both drugs into a single 
nanoparticle. The particles were prepared by a single emulsion, solvent evaporation technique, 
which resulted in particles with diameters of ~250 nm. Incorporation of the drugs into the 
nanoparticles resulted in ~8-fold higher uptake than for the free drugs in solution. The dual drug 
nanoparticle formulation also resulted in increased nuclear retention of doxorubicin. This was 
found to correspond to lower levels of expression of resistance genes MDR1 and BCl-2 in K562 
cells, attributed to curcumin inhibition. Combined, these properties resulted in increased in vitro 
cytotoxicity for the dual drug nanoparticles in comparison to doxorubicin nanoparticles or the 
dual drugs in solution. 
Curcumin was also encapsulated in another nanoparticle system developed by Mohanty and 
Sahoo.113 Curcumin was loaded in glycerol monooleate (GMO)/Pluronic F-127 particles using an 
emulsification technique upon the addition of 0.5% w/v polyvinyl alcohol. The nanoparticles 
displayed an average diameter of 192 ± 7 nm and had a spherical morphology. HPLC studies 
revealed an encapsulation efficiency of 90 ± 3%, and in vitro release experiments demonstrated 
an initial burst of 46% of drug released in 24 hours, after which the remaining drug was released 
over a period of 10 days. Similar to the cell uptake of curcumin-loaded micelles investigated by 
Mohanty et al., the authors found that cell uptake was concentration dependent, with lower 
concentrations of curcumin-loaded nanoparticles exhibiting better cell uptake than unmodified 
curcumin, in addition to more effective anti-proliferative activity. 
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Sindhu et al. synthesized spherical gold nanoparticles using curcumin alone as a reducing 
agent.114 The particles were spherical, with an average size of 58 nm and a zeta potential of -23 
mV. The authors reported that the particles were stable at room temperature for up to 6 months, 
and that they were non-toxic in vitro. Mesoporous silica nanoparticles (MSN) (type MCM-41) 
have also been used to encapsulate curcumin within the pores of the nanoparticles in order to 
enhance its solubility.115 The authors demonstrated that the solubility of curcumin encapsulated 
in the silica nanoparticles (0.53 µg/mL) was increased by 71% compared to that of curcumin 
alone (0.31µg/mL) and curcumin-MSN physical mixture (0.36 µg/mL). The authors noted that in 
vitro curcumin release was much more rapid when encapsulated in the MSN, reaching 29% over 
72 hours due to the formation of curcumin nano-aggregates in the pores, compared to 8.9% and 
9.0% as demonstrated by curcumin and curcumin-MSN physical mixture, respectively. This 
resulted in enhanced cytotoxic effects for curcumin-MSN on human breast cancer cells 
compared to free curcumin and curcumin-MSN physical mixture.  
2.5.2.5 Hydrogels 
Though not formally nanomaterials in their simplest form, hydrogels, composed of networks of 
polymer chains, are high water-content materials that can possess strength and flexibility similar 
to human tissue (Figure 2.10).116 Because there exists a large array of water-soluble polymers 
that can be used for the preparation of hydrogels having a wide variety of physical morphologies 
(eg. particles, slabs, and films) and properties, hydrogels can potentially be used for many 
different biomedical applications including drug delivery. Curcumin-encapsulating hydrogels 
containing 0.5, 1, or 2 wt% of a 20 amino acid peptide referred to as MAX8, have been 
synthesized via a self-assembly method upon the addition of salt solution buffered to pH 7.4 or 
cell culture medium at the same pH, where curcumin-encapsulation and hydrogel formation 
occurs concurrently.117 Hydrogels containing curcumin displayed solid-like properties even after 
shear thinning, where they were capable of re-healing quickly according to the oscillatory 
rheology and shear stiffness study conducted. This suggested their potential as injectable 
materials for localized curcumin delivery. The release of curcumin occurred over a period of 14 
days and could be modulated to some extent as a function of the MAX8 peptide concentration. In 
addition, through in vitro experiments, it was demonstrated that the presence of curcumin in the 
 hydrogels inhibited the growth of human medulloblastoma cells on the hydrogel. The bioactivity 
of the released curcumin was also confirmed by its ability to inhibit growth of the same cell line. 
Figure 2.10: Schematic of a hydrogel with encapsulated curcumin
An emerging field of hydrogels, called “smart” hydrogels, has
hydrogels are capable of dramatically changing their properties in response to stimuli such as 
temperature, pH, and chemicals.
hydrogel for brain targeting applications through intranasal administration.
synthesized using Pluronic F127 and Poloxamer 188. The curcumin
sol-gel transition in the temperature range 32
physiological temperatures. In vitro
within 6 hours, and in vivo studies showed that curcumin
one hour to pass from the nasal cavity of rats to their oropharynx. In addition, brain tissue 
distribution analyses showed the presence of curcumin in the cerebellum, cerebrum, 
hippocampus, olfactory bulb, and plasma after the administ
hydrogel. This suggests the application of these curcumin hydrogels for targeting of brain 
tumours.  
2.5.2.6 Dendrimers and Proteins
In addition to assemblies of phospholipids and polymers into which curcumin can be physically 
encapsulated, dendrimers have also been widely studied for drug delivery and have often been 
used for the preparation of covalent drug conjugates
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Hydrogels were 
 
 polymers with precise architectures
structures are prepared on a generation
applications. Shi et al. used dendrimers
effects in the dissolution of amyloid fib
curcumin where one of the phenolic groups of curcumin was modified with azide, alkyne, or 
carboxylic acid. These monofunctional derivatives of curcumin were then used to produce other 
forms of curcumin, among them a polyamidoamine (PAMAM) dendrimer
(Figure 2.11). The PAMAM-curcumin conjugate was synthesized using a fourth generation 
PAMAM dendrimer with a cystamine core and amine surface groups. Curcumin monocarboxylic 
acid was coupled to the amine termini
hydroxysuccinimide, and triethanolamine. The biological activity of curcumin was not disrupted 
by its chemical modification as reported; In fact the chemical properties of curcumin were 
enhanced. The water-soluble PAMAM
amyloid fibrils in vitro. The enhanced water solubility of curcumin by attachment to dendrimers 
suggests promising therapeutic applications
Figure 2.11: Schematic of the synthesis of a curcumin
In another study, with the aim of understanding curcumin's wound healing properties despite its 
rapid degradation in aqueous solution, the stabilization of curcumin by
proteins, human serum albumin (HSA), fibrinogen, immunoglobulin G (IgG), and transferrin 
was investigated.123 It was reported that curcumin degradation was suppressed with a yield of 
94.2 ± 13.9% when stabilized with HSA, and 93.6 ± 
 that result from their step-wise synthesis.121
-by-generation basis, they can be tailored for use in many 
 for the enhancement of curcumin’s bioavailability and its 
rils.122 The group produced monofunctional d
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suppress curcumin degradation as efficiently (47.8 ± 14.1%), and IgG had no effect on 
degradation. The impressive degradation suppression of HSA and fibrinogen were attributed to 
the hydrophobic interactions between the proteins and curcumin, where binding of curcumin 
takes place in the hydrophobic pocket in the protein. This eliminates interactions with 
surrounding water molecules inhibiting curcumin degradation by hydrolysis. 
2.6 Conclusions and Future Prospects 
With the potential application of the wide range of above vehicles as drug delivery systems come 
several challenges. Vesicles often require complex preparation procedures, and are often too 
large for drug delivery applications. The large size (> 200 nm) results in clearance by the 
reticuloendothelial system (RES) thereby eliminating the drug from the circulatory system.124 
Nanoparticles are also often too large to exhibit long circulation times in vivo, frequently having 
diameters > 200 nm. In addition, they have some tendency to exhibit an undesirable "burst" 
release of the drug. Micelles on the other hand are smaller, and can sometimes exhibit long 
circulation times in vivo. However, as they are prepared by self-assembly approaches, their 
behaviour in vivo in the presence of membranes and hydrophobic serum proteins, will not always 
be the same as their in vitro behaviour in simpler model systems. In addition, the metabolic fate 
of these carriers is often difficult to determine, and some may not be biodegradable. 
Nevertheless, the work this far has demonstrated the great potential of drug delivery systems to 
overcome some of curcumin's problematic properties such as its extremely low aqueous 
solubility, stability, and bioavailability. 
Although there is still much to be investigated with respect to curcumin and its therapeutic 
properties, it has great potential in cancer therapy and prevention. Curcumin is proposed to exert 
its anti-cancer effects through a variety of mechanisms including the down-regulation of NF-κB, 
the suppression of AP-1 activity, various effects on STAT proteins, as well as other mechanisms. 
The controversy regarding curcumin's chemical structure in aqueous solution at neutral pH 
appears to be solved, with the dominance of the keto-enol form well supported by NMR 
spectroscopy as well as theoretical studies. However, there is still debate as to whether it is 
curcumin itself or its degradation products that provide the observed biological activities. This 
issue highlights one of the main challenges in working with curcumin - its susceptibility to rapid 
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degradation in a wide range of environments and its sensitivity to pH and light. Other major 
challenges include curcumin's extremely low aqueous solubility and bioavailability. While 
curcumin has been safely administered at high doses in many clinical trials, has achieved the 
status of GRAS, and is marketed as a dietary supplement in many countries, it has yet to be 
licensed as a drug, likely due to the above-mentioned limitations as well as its multi-target 
property. 
To address the solubility and bioavailability limitations, a variety of approaches have been 
explored to improve its solubility and to deliver it to cancer cells. The formation of co-crystals 
with a variety of molecules has resulted in significant enhancements in the curcumin dissolution 
rate. Liposomes, micelles, nanoparticles, and other delivery systems have generally led to 
enhanced curcumin solubility, stability, cell uptake, and improved biological activities, and are 
starting to be evaluated in clinical trials. 
Despite the immense progress made on the study and application of curcumin over the last 
couple of decades, many questions and challenges still exist. For example, it will be critical to 
determine whether the biological properties of curcumin indeed result from the parent compound 
or from its degradation products. This is important not only for the fundamental understanding of 
this drug but also because the drug delivery systems tend to stabilize curcumin, an advantage that 
only persists if this is the bioactive molecule. It will also be important to continue the 
development of viable drug delivery systems for curcumin. Here, the critical aspects will involve 
the enhancement of curcumin solubility and bioavailability, as well as approaches for selectively 
targeting these delivery systems to the disease sites. With this promising progression, the use of 
curcumin for the treatment of cancer and other diseases can be envisioned in the near future.  
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Chapter 3  
3 Synthesis, Characterization, and in vitro Activity of 
Curcumin-Loaded Folic Acid-Conjugated Magnetic 
Nanoaggregates 
3.1 Introduction 
For many years cancer has been, and still remains, one of the most difficult diseases to treat. 
Despite the sophisticated cancer treatment methods available today compared to when cancer 
was first discovered, there remain several drawbacks to the available options. With surgery being 
too invasive in many cases, and chemotherapy presenting many adverse side effects such as 
vomiting and nausea, hair loss, and liver damage, there has been a drift away from synthetic 
pharmaceuticals towards the use of natural medicines. One such medicine is curcumin—a natural 
polyphenol derived from turmeric—which has been shown to inhibit cancer cell survival by 
inducing apoptosis, and arresting different phases of the cancer cell cycle.1 Due to curcumin’s 
poor solubility, there is a strong need for a technology that not only enhances the solubility of 
curcumin, but can also transport it to the site of interest in order to avoid its clearance from the 
body, and decrease the required dose for treatment.  
Of particular interest are magnetic nanoparticles (MNP) due to their small size, biocompatibility, 
high stability and surface area, and magnetic properties.2 Because these nanovehicles can be 
tailored in terms of size, morphology, and surface chemistry, they have been identified as a 
promising technology for virus detection,3 the promotion of human fibroblast growth,4 and most 
importantly as contrast agents for diagnosis of cancer using magnetic resonance imaging (MRI).5 
Their use as contrast agents for cancer diagnosis has also inspired interest in their use as drug 
delivery systems for the potential treatment of cancer.6 Of the available MNP, magnetite (Fe3O4) 
has been found in the teeth of chitons, honey bees, homing pigeons and magnetotactic bacteria 
and algae, and is generally used as a navigation device.7 Therefore, it is interesting to investigate 
this navigational system in humans. Common synthesis methods of iron oxide nanoparticles 
include precipitation, thermal decomposition, and hydrothermal/solvothermal synthesis.8 
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In order to enhance the stability of curcumin and increase its bioavailability for cancer treatment 
it is possible to incorporate it onto magnetite. This can potentially decrease the amount of time it 
is left in the circulatory system, thereby avoiding first pass clearance by the reticuloendothelial 
system (RES), and it can also decrease the dose required for treatment. Yallapu and coworkers 
have explored the potential of curcumin as an anticancer agent,9 and have worked on its 
incorporation into magnetite delivery systems. In 2011, Yallapu et al. synthesized β-
cyclodextrin/pluronic F127 coated magnetite nanoparticles through the co-precipitation of Fe2+ 
and Fe3+ iron salts in the presence of ammonia.10 This water dispersible system was tested for 
hyperthermia, MRI, and drug delivery applications, and showed superior activity for all three 
applications compared to pure iron oxide, and β-cyclodextrin-coated iron oxide. In 2012, the 
same group synthesized β-cyclodextrin/pluronic F68 coated magnetite nanoparticles using the 
same co-precipitation method, and the nanoparticles were then loaded with curcumin.11 The 
drug-loaded nanoparticles had an average aggregate size of 123 nm and showed controlled 
curcumin release for up to 28 days. Furthermore, the authors reported good cellular uptake and 
toxicity in MDA-MB-231 breast cancer cells. Curcumin loaded nanoparticles developed by 
Yallapu et al. were also tested in vitro in two human pancreatic cell lines, and in vivo in mouse 
models.12 The nanoparticles inhibited the growth of pancreatic cancer cells, and improved 
survival of mice by delaying tumour growth. Furthermore, the bioavailability of curcumin in 
mice increased 2.5-fold when using drug loaded iron oxide nanoparticles, as compared to free 
curcumin.  
Several other researchers have worked to incorporate curcumin into magnetite-based 
nanovehicles for cancer treatment. For example, Wang et al. developed a core-shell drug 
delivery system consisting of a commercial amine modified iron oxide core covalently bound to 
a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer shell.13 
These nanoparticles were reported to have a diameter of 113 nm as measured by DLS, and 
magnetite cores of 15 nm as measured by TEM. In vitro release studies showed 70% curcumin 
release over a period of 4 hours, which may need to be optimized for biomedical applications. 
Devkota et al. reported the development of a curcumin-loaded alginate/magnetite nanoconjugate 
for inductive heating and detection, which can be employed in hyperthermia, biodetection, and 
drug delivery applications.14 Nanoparticles were synthesized using the traditional co-
precipitation method, and were approximately 120 nm as measured by DLS. The authors also 
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reported a decreased saturation magnetization of the curcumin-loaded nanoconjugates (35 
emu/g) as compared to uncoated magnetite (60 emu/g); however, nanoconjugates showed a 
promising inductive heating capacity and high detection sensitivity, which is beneficial for 
hyperthermia and detection applications. Paulino et al. developed hydrogels from different 
natural polymeric networks loaded with 50 nm magnetite particles for controlled curcumin 
release.15 The authors demonstrated decreased hydrogel swelling in the presence of magnetite 
nanoparticles, in addition to magnetic field-induced curcumin release when the magnetite is 
stimulated using a magnetic field.  
With the promising results obtained by other researchers on the anti-cancer potential of 
curcumin-containing magnetite nanoparticles, we propose for the first time to the best of our 
knowledge a dual targeting curcumin delivery system for cancer treatment (Figure 3.1). 
Magnetite nanoaggregates, synthesized through the precipitation of a single iron salt, are coated 
with an amino functionalized poly(propylene glycol) (PPG-NH2), which is used to couple folic 
acid at its carboxylic acid. Magnetite nanoaggregates were also simultaneously coated with β-
cyclodextrin (β-CD) for curcumin encapsulation. Poly(propylene glycols) have been 
demonstrated to form complexes with β-CD, where the poply(propylene glycol) is weaved 
through the β-CD cavity.16, 17 The magnetic properties of the iron oxide core can allow the 
nanovehicle to be guided to the target site, while the folic acid acts as a ligand to selectively 
target the folate receptor, which is overexpressed on the cell surface of some cancer cells.18, 19 
This dual targeting system will allow for the destruction of cancerous cells meanwhile rendering 
the surrounding healthy tissue unharmed.  
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Figure 3.1: Schematic of a folic acid-conjugated curcumin-loaded magnetic nanoparticle 
3.2 Materials 
The iron precursor ferrous sulphate heptahydrate (FeSO4·7H2O) was purchased from VWR 
International. β-cyclodextrin (β-CD) (MW: 1135 g/mol) was purchased from Sigma-Aldrich 
along with poly(propylene glycol) bis(2-aminopropyl ether) (PPG-NH2) (MW: 2000 g/mol), 
curcumin (MW: 368 g/mol), and N, N-diisopropylethylamine (DIPEA) (MW: 129.25 g/mol).  
Folic acid (FA) (441 g/mol) and fluorescein isothiocyanate (FITC) (389 g/mol) were purchased 
from Alfa Aesar. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (MW: 155.24 g/mol) 
was purchased from Advanced ChemTech, and ammonium hydroxide (NH4OH) and 
dimethylsulfoxide (DMSO) were obtained from VWR.   
For the cell studies, MDA-MB-231 cells were obtained from American Type Culture Collection 
(Manassas, VA) and maintained in DMEM/F12 + 10% fetal bovine serum (FBS). MDA-MB-468 
cells were obtained from Dr. Janet Price (MD Anderson Cancer Center, Houston, TX) and 
maintained in αMEM + 10% FBS. All growth media and supplements were obtained from 
Invitrogen (Carlsbad, CA). FBS was obtained from Sigma-Aldrich (St. Louis, MO). All plastics 
were from Nunc™ (Thermo Fisher Scientific, Ottawa, ON). All cells were incubated at 37°C 
under a 5% CO2 atmosphere. 
poly(propylene glycol) bis(2-aminopropyl ether)
β-cyclodextrin folic acid curcumin
Fe3O4
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3.3 Synthesis Procedures 
Figure 3.2 shows the overall synthesis process, and the contents of each sample synthesized is 
summarized in Table 3.1.  
FeSO4·
H2N
O
NH2
CH3 CH3
n
+ NH4OH
-cyclodextrin ( -CD)
poly(propylene glycol) bis(2-aminopropyl ether)
(PPG-NH2)
H2O
S1 - S4
80 C, 90 mins.
folic acid
EDC/DIPEA
curcumin
acetone/H2O
curcumin
acetone/H2O
S1 - S4 S1FA - S4FA
(from S1 - S4)
S1FAc - S4FAc
(from S1FA - S4FA)
O OH
OH
OCH3
HO
H3CO
room temperature, 24 hr
O OH
OH
OCH3
HO
H3CO
room temperature, 24 hr
S1c - S4c
(from S1 - S4)
 
Figure 3.2: Chemical scheme of synthesis process 
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Table 3.1: Polymer compositions, and folic acid and curcumin content of synthesized 
samples 
Sample mmol PPG-NH2 : mmol β-CD (FeSO4·7H2O is constant at 5 mmol) Folic Acid Curcumin 
S1 0.25 : 1.0 - - 
S2 0.50 : 1.0 - - 
S3 1.0 : 0.50 - - 
S4 1.0 : 1.0 - - 
S1c 0.25 : 1.0 - + 
S2c 0.50 : 1.0 - + 
S3c 1.0 : 0.50 - + 
S4c 1.0 : 1.0 - + 
S1FA 0.25 : 1.0 + - 
S2FA 0.50 : 1.0 + - 
S3FA 1.0 : 0.50 + - 
S4FA 1.0 : 1.0 + - 
S1FAc 0.25 : 1.0 + + 
S2FAc 0.50 : 1.0 + + 
S3FAc 1.0 : 0.50 + + 
S4FAc 1.0 : 1.0 + + 
 
3.3.1 Preparation of PPG-NH2/β-CD Coated Nanoaggregates Sample 
S4 and Representative Procedure for the Preparation of Samples 
S1 – S3 
Magnetic nanoaggregates were synthesized based on a modified method reported by Ragab et 
al.20 1.40g (5 mmol) of the iron precursor FeSO4·7H2O were dissolved in 50 mL distilled water, 
and 2 mL (1 mmol) of PPG-NH2 was added to the dissolved precursor under stirring (400 rpm) 
and left until a colour change was noticed (green to orange/yellow). 1.20 g (1 mmol) of β-CD 
dissolved in 20 mL of ammonium hydroxide (NH4OH) was gradually added to this mixture, at 
which point stirring was immediately increased to 1200 rpm and the temperature was increased 
to 80°C. The mixture was covered and left for 90 minutes under stirring. The prepared sample 
(S4) was separated from the supernatant using a magnet and the supernatant was removed using 
a pipette. The particles were then redispersed in distilled water. The sample was then recollected 
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using the magnet and the distilled water was removed before the sample was redispersed in 
ethanol. The sample was washed 3 times in ethanol using this procedure, and then dried at 60°C. 
Samples S1 – S3 were prepared in the same manner, but the absolute amounts of PPG-NH2 and 
β-CD were reduced according to Table 3.1.  
3.3.2 Functionalization of PPG-NH2/β-CD-Coated Nanoaggregates 
Samples with Folic Acid 
Samples S1 – S4 were functionalized with folic acid using the following method. 20 mg (46 
µmol) of folic acid were dissolved in 10 mL of DMSO containing 20 μL (92 µmol) of DIPEA in 
a nitrogen atmosphere. This solution was added to 20 mg of dry polymer-coated nanoaggregates 
(S1 – S4), after which 10 mL of DMSO containing 7 mg (46µmol) of EDC was added under 
nitrogen. The samples were left shaking in a water bath for 2 days, initially at room temperature 
for the first 3 hours, after which the temperature was increased to 35°C. After removal of the 
samples from the water bath, the aggregates were left on a magnetic plate to settle completely 
before the folic acid content in the supernatant was analyzed using UV-visible spectroscopy to 
quantify the amount of folic acid attached. The folic acid functionalized nanoaggregates (S1FA – 
S4FA) were then separated using a magnet, the supernatant was removed, and the samples were 
redispersed in ethanol for washing. The samples were recollected with a magnet, the ethanol 
supernatant removed, and the samples were dispersed again in ethanol. This washing procedure 
was carried out 3 times, and the samples were dried at 50°C.  
3.3.3 β-CD/curcumin Complex Synthesis and Curcumin Loading of 
Nanoaggregates 
β-CD/curcumin complex was synthesized by adding a solution containing 36 mg ( ) of curcumin 
in 1.5 mL of acetone to a solution of 120 mg ( ) of β-CD in 24 mL distilled water under stirring 
(400 rpm). The mixture was left for 24 hours before the supernatant was collected by 
centrifugation and freeze dried for 24 hours to obtain a dry β-CD/curcumin complex solid. The 
synthesized complex, along with β-CD, and curcumin were analyzed using proton nuclear 
magnetic resonance (1H NMR). 
Nanoaggregate samples were loaded with curcumin via a modified method reported by Yallapu 
et al. to produce curcumin loaded samples.11 10 mg of nanoaggregates were dispersed in 2.8 mL 
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of distilled water under stirring at 400 rpm.  Curcumin (1.0, 1.5, 2.0, 3.0, or 5.0 mg) was 
dissolved in 200 µL of acetone and added dropwise to the nanoaggregate suspension. The 
mixture was stirred for 24 hours at room temperature. The resulting curcumin-loaded 
nanoaggregates (S1c – S4c and S1FAc – S4FAc) were thoroughly washed with distilled water by 
magnetically collecting the samples, removing the supernatant, and re-adding distilled water. The 
washing process was carried out 6 times. Samples were then freeze dried to obtain dry 
nanoaggregates. To determine the loading efficiency, 5.0 mg of curcumin loaded nanoaggregates 
were suspended in 10 mL of ethanol. The samples were left shaking in a water bath at 25 °C for 
24 hours, after which samples were removed from the water bath and placed on a magnetic plate 
to allow the nanoaggregates to settle. The supernatant was collected using a pipette and the 
curcumin content was measured using UV-visible spectroscopy at 427 nm. 
3.3.4 Preparation of FITC-labeled Particles 
1.0 mg FITC were dissolved in 3 mL acetone/water (0.3/2.7 v/v) mixture and added to a 
dispersion of magnetic nanoaggregates (10 mg) in 10 mL of PBS. The reaction was left stirring 
at 1000 rpm in the dark for 24 hours at room temperature. The resulting FITC-labeled samples 
were washed with PBS and stored at 4°C. Similar fluorescence of FITC-labeled samples was 
obtained, as measured by a Photon Technology International (PTI) fluorometer. 1 mg of FITC-
labeled nanoagreggates was suspended in 1 mL of PBS and measured at an emission range of 
450 – 650 nm, an excitation wavelength of 494 nm, a length of 200 nm, step size of 0.5 nm, and 
integration of 0.1 seconds. 
3.4 Characterization of Synthesized Nanoaggregates 
3.4.1 Particle Morphology 
The general morphology of the synthesized nanoaggregates was examined using a Philips CM 10 
transmission electron microscope operating at 80 kV. Samples were prepared on Formvar 
carbon-coated-100-mesh copper grids. One drop of a 0.50 mg/mL nanoaggregate suspension was 
used to cover the grid surface. Excess water was removed using fine filter paper, and the grid 
was left for approximately 30 minutes to dry in air prior to examination. 
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3.4.2 Particle Size Analysis 
The mean diameter of the individual particles and the polydispersity indices were determined 
using a Malvern Instruments Ltd. Zetasizer 3000 HSA particle sizer. The size analysis was 
performed at a scattering angle of 90° and room temperature. Nanoparticle suspensions (1.0 
mg/mL) were prepared and diluted by a factor of 45 to obtain homogeneous suspensions of 
nanoparticles. Three runs were carried out per sample in order to obtain a standard deviation. 
The aggregate size was determined using a Malvern Instruments Ltd. Zetasizer Nano ZS. 
Samples were prepared at concentrations of 0.50 mg/mL and analyzed at a measurement angle of 
173° at room temperature. Samples were run three times each in order to obtain a standard 
deviation value. 
3.4.3 X-ray Diffraction (XRD) Analysis 
The crystal structures of the samples were analyzed using a Rigaku-Miniflex X-ray 
diffractometer (The Woodlands, TX). The samples were exposed to radiation (CuKα (30 kV, 15 
mA)) at a wavelength of 1.54 Å, and scanned over a 2θ range of 5 - 90° with a step size of 0.05°. 
3.4.4 Fourier Transform Infrared (FTIR) Spectroscopy 
A Bruker-Tensor 27 (Germany) spectrophotometer was used to obtain the FTIR spectra of the 
samples in the solid state. Samples were mixed with potassium bromide in a 1.0:10 w/w ratio and 
pressed into a disc prior to examination. Samples were scanned between 4000 – 600 cm-1 at a 
scanning speed of 4 cm-1. 
3.4.5 Vibrating Sample Magnetometer (VSM) Measurements 
A model 74035 VSM was used to explore the magnetic properties of the samples. 
Approximately 15 mg of sample were added in the sample holder, after which the samples were 
exposed to a magnetic field at a field range of ±10000 G. 
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3.5 In vitro Studies Experimental Procedures 
3.5.1 Curcumin Release 
In vitro curcumin release was carried out at 37°C in a water bath under constant shaking. Briefly, 
1.0 mg of curcumin-loaded nanoaggregates was dispersed in 10 mL of PBS containing 0.10% 
Tween 80. At predetermined intervals, the supernatant was collected and fresh buffer/Tween 
solution was replaced in the sample vials. The collected supernatant was measured using UV-
visible spectroscopy at 427 nm. 
3.5.2 In vitro Cytotoxicity Assays 
MDA-MB-231 and MDA-MB-468 cells were plated in 100 µL of culture medium at a density of 
2.5 x 104 cells/well in 96-well plates. After 24 hours, various treatments (sample S2, sample S2c, 
sample S2FA, sample S2FAc [up to 2000 μg/mL of particles], or free curcumin [up to 260 
μg/mL] (Sigma-Aldrich, St. Louis MO)) were added to the cells and incubated for 48 hours. Cell 
viability was determined using the Alamar Blue Assay (Life Technologies, Inc., Burlington, 
ON). 
3.5.3 Flow Cytometry Analysis 
For assessment of folate receptor expression, human breast cancer cells were harvested and 
stained with a mouse anti-human folate receptor antibody (LK26, AbcamInc, Cambridge MA) 
for 30 min at 4 °C. After removal of excess antibody by PBS washing, cells were incubated with 
AlexaFluor488-conjugated goat anti-mouse IgG (Life Technologies) for another 30 min at 4 °C, 
washed with PBS, and analyzed by flow cytometry using a Beckman Coulter EPICS XL-MCL 
flow cytometer. 
For assessment of nanoparticle uptake, human breast cancer cells were seeded into 60mm culture 
dishes and grown until 80% confluent. FITC-labeled sample S2or S2FA (2000 µg/mL) were 
added to the cells. After 4 hours incubation at 37 °C, particles that were not internalized were 
washed away using PBS and cells were harvested. Extracellular FITC was quenched by 
incubating with 200 µg/mL Trypan Blue (Sigma-Aldrich) for 10 min at room temperature. Cells 
were washed using PBS and analyzed by flow cytometry. 
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3.6 Results and Discussion 
3.6.1 Nanoaggregate Synthesis 
Magnetic nanoaggregate samples were synthesized using a precipitation method involving one 
iron salt, as compared to the traditional co-precipitation method where Fe2+ and Fe3+ salts must 
be used with the iron cations having a precise 1:2 molar ratio. The traditional method involves 
the need for strict oxidation control in order to avoid the formation of γ-Fe2O3 instead of Fe3O4, 
which requires a complicated experimental setup in order to run the reaction under a nitrogen 
atmosphere. Therefore, the method employed here is advantageous due to its simplicity and is 
carried out based on the following reactions:  
Fe2+ + 2OH-Fe(OH)2 
4Fe(OH)2 + O2 4FeOOH + 2H2O 
FeOOH + 2Fe(OH)2 + 5OH-  Fe3O4 + 5H2O + O2 
Nanoaggregates were synthesized by the addition of β-CD to a mixture of ferrous sulphate and 
PPG-NH2 under alkaline conditions (Figure 3.2), as a high pH promotes small particle 
formation,21 which is desirable for biomedical applications. Another factor that was employed to 
control the particle size was the addition of PPG-NH2, as this polymer can act as a stabilizer by 
adsorbing on the crystal structure surface.21 The resulting reduction in surface tension causes a 
reduction in the Gibbs free energy and consequently an increase in nucleation rate, resulting in 
smaller particle size. In solution, the metal component of the precursor forms seeds which allow 
the growth of metal ions or metal-stabilizer complexes (monomers) on the surface, forming 
crystals.21, 22 Therefore, with fast nucleation more seeds are present to consume monomers on 
their surfaces, yielding smaller particles (Figure 3.3). However, under conditions of slow 
nucleation, few seeds are produced, which consume a larger amount of the produced monomers 
on their surface. 
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Figure 3.3: Nucleation and growth schematic 
Figure 3.2 briefly outlines the synthesis process. PPG-NH2 and β-CD were added in different 
amounts as shown in Table 3 to obtain samples with varying PPG-NH2/β-CD ratios (S1 – S4), 
which were then used to produce folic acid functionalized samples (S1FA – S4FA). Samples 
with and without folic acid were then loaded with curcumin to obtain both folate positive, and 
folate negative drug loaded samples for future experiments (Table 3.1). 
3.6.2 Nanoaggregate Characterization 
The size of drug delivery vehicles is one of the most important parameters to be considered for 
biomedical applications. Particle size analysis was carried out to determine the size of both the 
individual particles, as well as the aggregates formed (Table 3.2). Generally, there was a slight 
decrease in the average individual particle size when the amount of PPG-NH2in the system was 
higher than the amount of β-CD, as demonstrated by the results for samples S1, S2, S3, and S4. 
This may be attributed to the interference of the polymer with the growth of the crystals upon 
adsorption on the crystal surfaces.21, 23 The desired size range of individual nanoparticles was 10 
– 20 nm. The sizes of the individual particles were measured by DLS following sonication for 5 
seconds followed by dispersion using a vortex and then immediate dilutions until a clear light 
yellow, homogeneous solution was obtained. Sample diameters were in the expected size range. 
Aggregates were also measured by DLS following dispersion using a vortex and allowing the 
sample to reach an equilibrium aggregation state. Aggregates grow to decrease surface energy, 
and aggregation is generally dependant on particle-particle interactions.21 In general, samples 
formed smaller aggregates with increasing ratio of PPG-NH2:β-CD suggesting that PPG-NH2 
helps stabilize the particles, thereby decreasing particle-particle interactions. However, S2 did 
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not follow this trend completely. The specific ratio of PPG-NH2 to β-CD present in S2 may be 
ideal for decreasing particle-particle interactions which may explain why the aggregate size is 
less than the other samples. 
Table 3.2: Individual particle sizeand aggregate size of synthesized samples 
Sample S1 S2 S3 S4 
Aggregate Diameter (nm) 1000 ± 75 223 ± 10 443 ± 9 355 ± 5 
Polydispersity index 0.35 ± 0.09 0.30 ± 0.06 0.31 ± 0.06 0.43 ± 0.02 
Individual Particle Diameter (nm) 13 ± 5.6 10 ± 6 9.1 ± 3.4 11 ± 6.5 
Polydispersity index 0.20 ± 0.1 0.24 ± 0.07 0.28 ± 0.07 0.27 ± 0.1 
Samples were chosen for transmission electron microscopy (TEM) analysis in order to study the 
morphologies of the nanoaggregates. Uncoated nanoaggregates and sample S2 were chosen as 
representative samples for comparison (Figure 3.4). Images confirmed that the nanoparticles 
have spherical, uniform morphologies that form aggregates. However, this aggregation is 
reversible, meaning that certain techniques can be employed to obtain individual nanoparticles. 
One such technique is the use of surfactants or surface coatings at specific pH values to create a 
surface charge on the iron oxide nanoparticles.21, 24 Such surface charges can create repulsive 
forces, promoting deaggregation. This is demonstrated on iron oxide nanoparticles upon polymer 
coating, when compared to uncoated samples (Figure 3.4).  
In other work, Stuyven et al. showed that deaggregation of Ludox® silica sol samples in a KNO3 
solution depended on the presence of a magnetic field (0.31 T), and the type of flow.25 The 
authors showed that in the presence of a magnetic field, under turbulent flow conditions, particle 
size decreased (deaggregation) and a narrow size distribution was established. However, under 
laminar flow conditions (such as that seen in blood flow) aggregation was the dominant 
condition even with the presence of a magnetic field. This was attributed to the movement of 
charged particles to the channel wall where velocity is low. Based on this study, it would be 
interesting to employ a similar experiment on the current iron oxide samples—as they show 
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better magnetic properties than silica—by increasing the magnetic field gradually under laminar 
flow conditions and recording the aggregation behaviour.  
 
Figure 3.4: TEM images of A) uncoated nanoaggregates, and B) sample S2 
For biomedical applications, it is not only important to optimize the surface properties of the 
delivery system, but also the amount of drug loaded. In order to maximize the amount of 
curcumin in the system, it is beneficial to have more β-CD than PPG-NH2 in the nanoparticle 
system. For this reason, samples S1 and S2, along with their folic acid conjugated counterparts 
(S1FA and S2FA), were chosen for future experiments. Also, samples S2 and S2FA were chosen 
as representative samples for the remainder of the characterization studies used.  
X-ray diffractometry (XRD) was used to analyze the crystallinity of the iron oxide samples. 
XRD was carried out on uncoated nanoaggregates, and samples S2 and S2FA to ensure that the 
samples produced are in fact magnetite, and that their crystal structure remained unchanged after 
polymer coating, and folic acid functionalization. The five characteristic peaks noted for each 
sample are at 2θ angles of approximately 30°, 35°, 43°, 57°, and 62° (Figure 3.5a) with the same 
relative intensities, indicating a retained crystal structure of nanoparticles as peak shifting was 
not observed. Furthermore, the peak positions along with the relative peak intensities of each 
sample were compared with the standard XRD pattern for magnetite corresponding to ICCD card 
number 00-019-0629 obtained using the PDF-4+ software (Figure 3.5b).The full standard 
magnetite XRD pattern corresponding to ICCD card number 00-019-0629 is presented in 
Appendix 1. It was verified that the synthesized nanoparticles are magnetite based on the peak 
(a) B(b)
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position and intensities of the standard XRD pattern, which matched those obtained by the 
synthesized samples. Magnetite has the chemical formula Fe3O4 where the iron component 
consists of both FeII and FeIII. Magnetite has an inverse spinel structure where the FeII ions are all 
in octahedral sites and the FeIII  ions occupy both tetrahedral and octahedral sites.26 In addition, 
the oxygen atoms have a face centred cubic close packed alignment along [111]. 
 
Figure 3.5: a) XRD spectra of synthesized samples, and b) standard XRD pattern of 
magnetite (See Appendix 1). 
The magnetic properties of uncoated nanoaggregates, and sample S2 were studied to determine 
how the magnetic properties of Fe3O4 are affected by the presence of surface coatings (Figure 
3.6a). Magnetite is ferrimagnetic at room temperature due to the presence of at least two 
sublattices composed of the two different cationic sites in the structure (tetrahedral site of Fe3+ 
and octahedral site of both Fe3+ and Fe2+).27 However, magnetite shows super-paramagnetic 
behaviour as the size of the particles decreases (~≤ 20 nm),27, 28 and as a result of the easy 
magnetization along the crystallographic axis [111] present in the structure.26 This is evident by 
the low coercivity of each sample (Figure 3.6b) which is characteristic of super-paramagnetic 
materials. Surface modification of the nanoparticles decreased the saturation magnetization (Ms) 
and the corresponding magnetic properties, but not significantly, which is beneficial for the 
desired application. 
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Figure 3.6: a) Magnetization curves of uncoated nanoaggregates and sample S2 and b) 
their corresponding magnetic properties. 
Because nuclear magnetic resonance (NMR) could not be used to verify the presence of certain 
functional groups due to the magnetic properties of the aggregates, FTIR spectra of uncoated 
nanoaggregates, β-CD, PPG-NH2, and samples S2 and S2FA were obtained in order to ensure 
the successful synthesis of nanoparticles, and coupling of folic acid on the amino terminus of the 
PPG-NH2. FTIR spectra are presented in Figure 3.7, and the major peaks at wavenumbers higher 
than 1500 cm-1 are indicated. A peak is observed on uncoated magnetite nanoaggregates at 
approximately 3450 cm-1 due to O-H stretching vibrations (Figure 3.7a), in addition to the peak 
present at 1630 cm-1 corresponding to H-O-H stretching vibrations of residual water in the 
sample.29 As shown in Figure 3.7b for β-CD, the broad stretch between 3000 cm-1 and 3500 cm-1 
corresponds to the presence of O-H groups of β-CD and the peak at 1630 cm-1 is characteristic of 
H-O-H stretching vibrations.30 β-CD also has a characteristic peak at 2900 cm-1 caused by C-H 
stretching vibrations of CH2. The infrared spectrum of PPG-NH2 (Figure 3.7c) contains a strong 
peak between 2800 cm-1 and 3000 cm-1 corresponding to C-H stretching. For S2, as shown in 
Figure 3.7e, a combination of these peaks corresponding to the magnetite, β-CD, and PPG-NH2 
were observed. Sample S2FA (Figure 3.7f) also includes these characteristic peaks, however the 
C-H stretch intensity between 2800 cm-1 and 3000 cm-1 is decreased and the peak in the region of 
3000 – 3500 cm-1is broadened, suggesting the possible presence of an N-H stretch from the 
amide bond that is formed upon conjugation. Two peaks were also observed in the region of 
Sample
Saturation 
Magnetization 
(Ms) (emu/g)
Remnant 
Magnetization 
(Mr) (emu/g)
Coercivity (G)
uncoated
nanoaggregates
73.6 3.1 26.0
sample S2 69.8 2.0 15.4
(b)
-100
-80
-60
-40
-20
0
20
40
60
80
100
-10000 -5000 0 5000 10000
M
o
m
e
n
t/
M
as
s 
(e
m
u
/
g
)
Magnetic Field (G)
uncoated 
nanoaggregates
sample S2
-30
-20
-10
0
10
20
30
-500 0 500
(a)
63 
 
1600 – 1650 cm-1, suggesting the presence of a C=O stretch from the amide bond, adjacent to the 
H-O-H stretch.   
 
Figure 3.7: FTIR spectra of (a) uncoated nanoaggregates, (b) β-CD, (c) PPG-NH2, (d) folic 
acid, (e) sample S2, and (f) sample S2FA 
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The amount of folic acid attached was quantified to further ensure its presence on nanostructures. 
The amount of folic acid to nanoaggregates was selected through the modification of a method 
reported by Sun et al.31 The presence of folic acid conjugated to the amino terminals was 
measured to be 27±9% and 23±6% for samples S1FA and S2FA, respectively. This was 
calculated based on the folic acid content remaining in the supernatant (as measured by UV-
visible spectroscopy) following the coupling process using the following equation:  
 
%	
 =


× 100%      (1) 
where, wi is the weight of folic acid used in the coupling reaction, and ws is the weight of folic 
acid remaining in the supernatant. Despite S2 having more PPG-NH2 in the system, the amount 
of FA conjugated to S1 and S2 were statistically equivalent to one another.  
3.6.3 Curcumin Loading and in vitro Release 
To ensure curcumin’s presence within the β-CD cavities, a β-CD/curcumin complex was 
synthesized and studied using nuclear magnetic resonance (NMR). The characteristic chemical 
shifts of β-CD and curcumin were first determined (Appendix 2) and then used for comparison 
with the NMR spectrum of the synthesized complex. An NMR spectrum of the complex was 
obtained in deuterated water (Appendix 3) and only the chemical shifts of β-CD were observed. 
However, when an NMR spectrum of the complex was obtained in deuterated acetone (Appendix 
4) chemical shifts of both β-CD and curcumin are observed. Because curcumin is soluble in 
acetone, it acted to extract the curcumin from the β-CD cavities.  
In order to optimize the loading of curcumin, curcumin was added in varying amounts to samples 
S1 and S2 to obtain samples S1c and S2c, and the corresponding encapsulation efficiencies were 
obtained (Figure 3.8). The resulting trend revealed that the encapsulation efficiencies increased 
up to 0.3 mg/mg of MNP, then decreased at the highest curcumin amount of 0.5 mg/mg of MNP. 
Therefore, based on the results shown in Figure 3.8, the optimal amount of curcumin was chosen 
to be 0.3 mg/mg of MNP. At this loading ratio, encapsulation efficiencies of 73±4% and 86±5% 
were obtained for S1c and S2c, respectively, corresponding to drug contents of 23±1 % w/w and 
26±2 % w/w. Because S1 forms large aggregates as stated previously, the high aggregation may 
 hinder the ability of curcumin to enter the 
higher encapsulation efficiency compared to S1c.W
S2FA) were loaded at 0.3 mg/mg of MNP
lower encapsulation efficiencies of 41±4% and 31±
contents of 12±1% and 9.0±0.40%, respectively. This 
attributed to the presence of foli
cavity.  
Figure 3.8: Encapsulation efficiency trends for samples S1c and S2c
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surface may make it difficult for curcumin to securely enter the β-CD cavity and is left loosely 
encapsulated or entrapped on the surface. Based on these results, it is possible to optimize the 
release and sustain it for a longer period of time through the manipulation of the amount of PPG-
NH2, and consequently the amount of folic acid that will be on the surface.  
 
 
Figure 3.9: In vitro curcumin release profiles for (a) S1c, (b) S1FAc, (c) S2c, and (d) S2FAc 
To further analyze the release behaviour of the drug delivery system, it may be beneficial to 
describe each profile using a mathematical model. The Ritger-Peppas model can be used to 
describe the profiles obtained for each sample using the empirical equation shown below: 


= 	           (2) 
where  ∞  is the amount of drug released, k is the kinetic constant, t is the release time, and n 
is the diffusional exponent. Ritger and Peppas described controlled drug release from delivery 
0
20
40
60
80
100
0 0.5 1 1.5 2 2.5 3 3.5
C
u
m
u
la
ti
v
e
 %
 C
u
rc
u
m
in
 R
e
le
a
se
d
Time (days)
0
20
40
60
80
100
0 1 2 3 4 5
C
u
m
u
la
ti
v
e
 %
 C
u
rc
u
m
in
 R
e
le
a
se
d
Time (days)
0
20
40
60
80
100
0 0.5 1 1.5 2 2.5 3 3.5
C
u
m
u
la
ti
v
e
 %
 C
u
rc
u
m
in
 R
e
le
a
se
d
Time (days)
0
20
40
60
80
100
0 2 4 6 8 10 12
C
u
m
u
la
ti
v
e
 %
 C
u
rc
u
m
in
 R
e
le
a
se
d
Time (days)
(a) (b)
(c) (d)
67 
 
vehicles of different classical geometries, emphasizing the importance of the exponent, n, on the 
release behaviour.32-34 The authors summarized the results obtained for the values of the 
diffusional exponent for release from non-swellable systems of different geometries (Table 3.3). 
Table 3.3: Diffusional exponent and diffusion mechanism for non-swellable systems of 
different geometries34 
Diffusional exponent, n Drug Release 
Mechanism 
Thin film Cylindrical Spherical   
0.50 
0.50<n<1.0 
1.0 
0.45 
0.45<n<1.0 
1.0 
0.43 
0.43<n<1.0 
1.0 
Fickian diffusion 
non-Fickian transport 
zero-order release 
The values presented in Table 3.3 describe release behaviour with the assumption of one-
dimensional diffusion under perfect sink conditions. Also, the data presented by Ritger and 
Peppas correspond to monodisperse samples. However, with the presence of a particle size 
distribution, the expected values of n change. As described by Ritger and Peppas, the particle 
size distribution causes a significant acceleration of diffusion earlier in the release profile and a 
substantial retardation of release at longer times.  Based on the work of Ritger and Peppas, it is 
possible to determine whether the samples show Fickian or non-Fickian diffusion, however, 
further release studies must be conducted before a conclusion can be made about whether release 
is diffusion driven. 
3.6.4 In vitro Cell Studies 
Breast cancer cell lines MDA-MB-231 (231) and MDA-MB-468 (468) were selected as model 
cancer cells for in vitro experiments as they are clinically relevant cell lines which are available 
in the laboratory. Also, these cell lines have been used in other work involving folate 
targeting.35,36 However, these previous reports suggest contradictory information regarding the 
expression of the folate receptor by each cell line. For this reason, it was essential to determine 
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which cell line overexpresses the folate receptor relative to the other using an antibody labeling 
technique combined with flow cytometry. Figure 3.10 shows that 468 cells exhibit higher 
expression of the folate receptor relative to 231 cells. Therefore, it was expected that 468 cells 
would show higher particle uptake in future uptake experiments. Sample S2 and S2c along with 
their folic acid conjugated counterparts (S2FA, and S2FAc) were selected for in vitro 
experiments due to the relatively small size compared to other samples, and more sustained 
release compared to sample S1c. 
 
Figure 3.10: Folate receptor expression in MDA-MB-231 and MDA-MB-468 cells 
Next, the uptake of FITC-labeled particles into the 231 and 468 cells were investigated. As 
shown in Figure 3.11, S2FA exhibited 3.2-fold greater uptake into 231 cells than S2. This might 
be attributed to some folate receptor present on these 231 cells. The 468 cells, exhibited a higher 
level of MNP uptake in general, but the uptake was 3.9-fold higher for S2FA than S2. Overall, 
these results are consistent with the relative folate receptor expression on these cell lines but 
indicate only a modest difference in folic acid mediated uptake between 231 and 468. 
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 Figure 3.11: Uptake of samples S2 and S2FA by MDA
Before conducting cytotoxicity experiments with curcumin
assay was performed to determine at what concentrations the “free curcumin” was toxic to the 
cells. As shown in Figure 3.12, curcumin was non
approximately 26 μg/mL. Higher concentrations resulted in significant levels of toxicity. 
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Figure 3.12: Free curcumin dose response curve 
Based on these results, 231 and 468 cells were incubated with samples S2c and S2FAc at particle 
concentrations corresponding to curcumin concentrations in the range of 0.52 – 260 μg/mL. As 
shown in Figure 3.13, 231 cells treated with S2c were more resistant than 468 cells, which might 
result from the 231 cells being a highly aggressive breast cancer cell line.37 It may also be related 
to the lower uptake of MNP into these cells in general. At the highest concentration tested, 231 
cells treated with S2FAc showed slightly higher cell death than those treated with S2c but this 
difference was not statistically significant.  
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Figure 3.13: Cytotoxicity of curcumin-loaded nanoaggregates on breast cancer cells 
In terms of 468 cells, death resulting from treatment with both S2c and S2FAc treated cells was 
very similar. This can be attributed to the general susceptibility of 468 to treatment, as well as 
their increased uptake of the MNPs. It was demonstrated earlier that the encapsulation efficiency 
of curcumin in S2FAc is less than half of that in S2c and as a result there is less drug present in 
S2FAc. This means that for S2FAc to deliver the equivalent dose of drug as for S2c, more than 
twice as many particles must be taken up by the cells. This may cancel to some extent the 
increase in uptake mediated by the folate. 
To demonstrate that the toxicity indeed arose from curcumin rather than the MNPs itself, the 
toxicities of S2 and S2FA were evaluated in both 231 and 468 cells at the highest concentrations 
used in the above studies. As shown in Figure 3.14, at a concentration of 1000 μg/mL for both 
S2 and S2FA, 231 cells show no toxicity. In 468 cells, 1000 μg/mL of S2 shows slight cell death 
attributed to the toxic cationic charge present on the particle surfaces which is taken up by cells, 
however this cell death is decreased when folic acid is present (S2FA).This can be explained by 
the masking of this cationic charge by folic acid making the particles less toxic to cells. At a 
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 concentration of 2000 μg/mL, more cell death was observed for both 231 and 468 cells when 
treated with sample S2, but this level of cell death was less than that observed in the above 
studies with the curcumin-loaded particles, particularly for the FA
Figure 3.14: Cytotoxicity of samples S
3.7 Conclusion  
This chapter described the synthesis, characterization, and 
magnetite nanoparticles. Magnetic iron oxide nanoparticles were surface coated to incorporate a 
targeting ligand (folic acid) and a chemo
20 nm in size as measured by DLS and were noted to form aggregates of a few hundred 
nanometers to microns. It was demonstrated that this aggregation decreased with increasing 
amounts of PPG-NH2, however
aggregate size. FTIR analysis confirmed the presence of folic acid on the nanoparticles surfaces 
to serve as a targeting ligand for the folate receptor which is overexpressed on cancer cells 
surfaces. Furthermore, magnetization studies revealed that nanoaggregates retained their 
magnetic properties even after coating of the iron oxide core, which is required for the desired 
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application. In vitro curcumin release studies carried out on samples S1c and S2c, along with 
their folic acid-conjugated counterparts (S1FAc and S2FAc, respectively) demonstrated 
sustained release, over varying time periods. Sample S2c showed the best results in terms of 
controlled release, lasting for 11 days. However, sample S2FAc showed a higher burst effect 
than sample S2c suggesting that curcumin may have been only loosely encapsulated in sample 
S2FAc. Samples S1c and S1FAc showed similar release profiles, both demonstrating high burst 
effects and release lasting for approximately 3 days. Based on the release studies results, in vitro 
cell studies were carried out using samples S2 and S2FA on breast cancer cell lines MDA-MB-
231 and MDA-MB-468.  It was demonstrated that 468 cells are folate positive relative to 231 
cells, and as a results, 468 cells showed higher folate-mediated uptake of nanoparticles as 
compared to 231 cells. Cytotoxicity studies showed higher susceptibility of 468 cells to curcumin 
compared to 231 cells. Also, 468 cells treated with samples S2c and S2FAc showed similar cell 
viability, likely because S2FAc holds approximately half the amount of drug as S2c, meaning 
that approximately twice the amount of S2FAc is required to deliver the same amount of 
curcumin as sample S2. However, the flow cytometry results still confirm that the selective 
targeting by folic acid in sample S2FA, suggesting that this might be translated to an effect in 
vivo, under non-static conditions. Therefore, the results obtained support the notion that 
magnetite nanoparticles conjugated with folic acid can potentially be used for the controlled 
delivery of curcumin for potential chemotherapeutic applications. 
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Chapter 4  
4 Conclusions and Future Prospects  
To reduce the side effects induced by traditional chemotherapy, this thesis demonstrated a 
potential means of targeted delivery for a natural chemotherapeutic agent. Specifically, magnetic 
magnetite nanoparticles were synthesized through a simple method, conjugated with folic acid 
for ligand targeted treatment, and loaded with curcumin as a chemotherapeutic agent. An 
extensive review was presented in Chapter 2 on the chemical properties of curcumin, its 
biological activity/mechanisms of action as an anti-cancer agent, and previous approaches to its 
delivery.  
Chapter 3 described the experimental methods, results, and discussion. Synthesized magnetite 
nanoparticles coated with β-cyclodextrin (β-CD) and poly(propylene glycol) bis (2-aminopropyl 
ether) (PPG-NH2) were characterized using various techniques, which revealed that 
nanoparticles were 10 – 20 nm in size and formed micron-sized aggregates. XRD analysis 
ensured that the synthesized iron oxide samples were in fact magnetite, and magnetic studies of 
both coated and uncoated particles showed that the samples retained their magnetic properties, 
even after the magnetite core was coated. FTIR spectra ensured the presence of both coating 
agents on the surface, and the successful conjugation of folic acid to PPG-NH2.  
In vitro drug release studies were conducted in buffer in order to determine the rate of curcumin 
release. S2c containing more PPG-NH2, and S1c were investigated for sustained curcumin 
release and it was determined that S2c showed significantly better controlled release, lasting for 
11 days. The presence of PPG-NH2 likely increased the hydrophobic interactions, which must be 
broken for curcumin diffusion. However, for sample S2FAc the release of curcumin was faster, 
which was attributed to the presence of folic acid before curcumin loading, potentially making it 
difficult for curcumin to be entrapped securely in the β-CD cavities. Samples S1 and S1FA 
showed similar release profiles with high burst effects lasting for approximately 3 days. Based 
on these results, it may be possible to determine an optimum amount of PPG-NH2for folic acid 
conjugation which will demonstrate the most controlled curcumin release.  
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Sample S2 along with its folic acid conjugated (S2FA) and curcumin loaded counterparts (S2c 
and S2FAc) were chosen for in vitro experiments conducted on MDA-MB-231 (231) and MDA-
MB-468 (468)breast cancer cells. It was demonstrated that 468 cells are folate receptor positive 
compared to 231 cells, and this was supported by the ligand-mediated uptake of folic acid-
labeled magnetite samples (S2FA) by 468 cells compared to the relatively little uptake shown by 
231 cells. In vitro cytotoxicity studies were carried out on samples S2c and S2FAc. The results 
demonstrated more cell death in 468 cells than 231 cells, as 231 cells were relatively folate 
negative and are a more treatment-resistant cell line. In addition, the amount of curcumin in 
folate-labeled nanoaggregates is approximately half of that present in non-labeled 
nanoaggregates which was why 468 cells showed similar cell death for both folic acid-labeled 
and non-labeled samples. In general, curcumin delivered by nanoaggregates is more toxic to 468 
cells than 231 cells. 
With the promising results obtained by these studies, it would be interesting to evaluate these 
systems in vivo and to investigate the effects of magnetic targeting in the enhancement of 
cytotoxicity in the future. Also, it would be beneficial to track these nanovehicles using MRI 
while simultaneously acting as a chemotherapeutic agent. In order to achieve this, it would also 
be ideal to reduce the degree of aggregation of the particles under physiological conditions so 
that they can be administered intravascularly and can exhibit prolonged circulation in the blood. 
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Appendix  
Appendix 1: Standard XRD pattern for magnetite corresponding to ICCD card number 
00-019-0629 
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Appendix 2: 1H NMR spectra of curcumin and β-cyclodextrin 
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81 
 
 
 
 
 
 
 
 
 
 
β-cyclodextrin
82 
 
Appendix 3: H1 NMR of β-CD/curcumin Complex in Water 
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Appendix 4: H1 NMR of β-CD/curcumin Complex in Acetone 
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Figure 2.3:  
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